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Abbreviations 
 
3DE, three-dimensional echocardiography  
AP, antero-posterior 
ALPM, anterolateral-posteromedial 
CC, commissural 
CS, coronary sinus 
DMR, degenerative mitral regurgitation 
FMR, functional mitral regurgitation 
HF, heart failure 
IMR, ischemic MR 
LA, left atrium 
LV, left ventricle/ventricular 
LVEF, left ventricular ejection fraction  
LVOT, left ventricular outflow tract 
MA, mitral annulus 
MR, mitral regurgitation 
MSCT, multi-slice computed tomography 
MV, mitral valve 
nIMR, non-ischemic mitral regurgitation 
TA, trans-apical 
Ta, tras-atrial 
TS, trans-septal 
TMVR, transcatheter mitral valve replacement 
TEE, transesophageal echocardiography  
TPE; transpericardial echocardiography 
TTE, transthoracic echocardiography  
VHD, valvular heart disease 
vps, volumes per second 
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Abstract  
 
Background: Transcatheter mitral valve replacement (TMVR) is a new therapeutic option for high 
surgical risk patients with mitral regurgitation (MR) and several prostheses are currently at different 
stages of development. Indeed, once prototypes of these prosthesis are designed, they need to undergo 
both bench testing and preclinical evaluation to test the performance and safety of the device and 
acquire useful information for guiding the secondary improvements. After this stage, if the prosthesis 
shows favourable results in terms of performance and safety, the manufacturer can apply for CE 
marking. In case of achievement of the CE mark, the clinical use can start in the European countries. 
The application of advanced echocardiography is useful not only in a preclinical experimental stage 
but results to be an irreplaceable tool in the proper selection of the treatment strategy with respect to 
the case-specific anatomic and functional mitral valve (MV) disease pattern and in the guidance of 
the correct bioprosthesis positioning and implantation during the procedure.  
Aims: To describe the feasibility and advantage of 3D and contrast echocardiography in a preclinical 
study and report the acute hemodynamic results after implantation of a novel transcatheter self-
expandable D-shape mitral bioprosthesis characterized by asymmetric stent and advanced mono-
leaflet structure. In addition, we aimed to assess the MV geometry in patients with functional MR 
(FMR) that would potentially benefit from TMVR, focusing on the comparison between mitral 
annulus (MA) geometry of patients with ischemic (IMR) and non-ischemic mitral regurgitation 
(nIMR). 
Methods: From May 2015 to August 2018, prosthesis prototypes were implanted under 
echocardiography guidance in 112 small-size healthy sheep using both trans-atrial (Ta) and trans-
apical (TA) access. Multimodality imaging was used for animal selection and trans-pericardial 
echocardiography (TPE) was applied to obtain humanized image during intervention. Particle 
imaging velocimetry was used to assess intraventricular flow dynamics. We retrospectively selected 
94 patients with severe FMR, both IMR and nIMR. 3D MA analysis was performed in early-diastole 
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and mid-systoleby using a recent, commercially-available software package. Measure of interest were 
MA dimensions and geometry parameters, left atrial and left ventricular volumes. 
Results: 2D and 3D TPE was performed before and after implantation to measure MA dimensions 
(area: 6.4±0.8 cm2, perimeter: 9.4±0.8 cm) and assess prosthesis alignment and function. The vast 
majority of implantations showed none or just trivial intra- (n=104, 93%) and peri-prosthesis leak 
(n=86, 77%) with good valve function (mean gradient 4 ± 3 mmHg). At particle imaging velocimetry, 
left ventricular vortex properties did not change after implantation. 
In patients with severe FMR, 41 (43,6%) with IMR and 53 (56,4%) with nIMR, maximum MA 3D 
area (10.7±2.5 cm2 vs 11.6±2.7 cm2, p=0.124) and the best fit plane MA area (9.9±2.3 cm2 vs 10.7±2.5 
cm2, p=0.135, respectively) were similar between IMR and nIMR. nIMR patients showed larger mid-
systolic 3D area (9.8±2.3 cm2 vs 10.8±2.7 cm2, p=0.046) and perimeter (11.2±1.3 cm vs 11.8±1.5 cm, 
p=0.048), longer and larger leaflets, and wider aorto-mitral angle (135±10° vs 141±11°, p=0.011). 
Conversely, the area of MA at the best fit plane did not differ between IMR and nIMR patients (9±1.1 
cm2 vs 9.9±1.5 cm2, p=0.063).  
Conclusions: In the healthy sheep model, initial preclinical experience with a novel mono-leaflet 
transcatheter self-expandable mitral prosthesis showed that the TA implantation of the valve was 
feasible, safe, and supported by good hemodynamic results. The application of advanced 
echocardiography on an animal model was feasible and helpful in guiding the continuous refinements 
needed to enhance the development of this new concept of bioprosthesis.  
Patients with ischemic and non-ischemic etiology of FMR have similar maximum dimension, yet 
systolic differences between the two groups should be considered to tailor prosthesis’s selection. 
  
 7 
Riassunto 
 
Premesse: La sostituzione percutanea della valvola mitralica rappresenta una nuova opzione 
terapeutica per i pazienti con insufficienza mitralica (IM) ad alto rischio chirurgico. Attualmente 
molte protesi percutanee sono in differenti fasi di sviluppo. I prototipi valvolari, prima di ottenere il 
marchio CE ed iniziare l’uso clinico, devono essere sottoposti a test su animale per raggiungere il 
design finale. Inoltre, la valutazione della geometrica valvolare mitralica è fondamentale per il 
successo procedurale e l’ecocardiografia transtoracica 3D rappresenta un utile strumento di screening. 
Scopi: Valutare la fattibilità dell’impianto e i risultati emodinamici in acuto di una nuova bioprotesi 
percutanea auto-espandibile caratterizzata da una forma a D con stent asimmetrico e da un unico 
lembo. Valutare la geometrica della valvola mitralica in pazienti con IM funzionale (IMF) che 
potrebbero potenzialmente beneficiare della sostituzione percutanea della valvola mitralica, 
confrontando i pazienti con IMF secondaria a cardiopatia ischemica (IMF-I) e non-ischemica (IMF-
nI). 
Metodi: Da Maggio 2015 ad Agosto 2018 sono stati impiantati prototipi della nuova bioprotesi su 
112 ovini sani di piccola taglia usando l’approccio trans-atriale (Ta) e trans-apicale (TA). La 
selezione degli ovini è avvenuta mediante tomografia computerizzata ed ecocardiografia, mentre 
l’impianto è stato guidato tramite ecocardiografia trans-pericardica (ETP) che ha permesso di ottenere 
immagini “umanizzate”. Inoltre, l’analisi della velocità delle particelle è stata utilizzata per valutare 
la dinamica del flusso intracavitario prima e dopo impianto della bioprotesi. 
Sono stati retrospettivamente selezionati 94 pazienti con IMF severa. L’analisi 3D dell’AM è stata 
eseguita su immagini 3D dedicate, utilizzando un nuovo software d’analisi disponibile in commercio, 
in due momenti del ciclo cardiaco (protodiastole e mesosistole). Sono state misurate le dimensioni e 
la geometria dell’AM e i volumi atriali e ventricolari sinistri. 
Risultati: ETP 2D e 3D è stata utilizzata per misurare le dimensioni dell’AM nel modello ovino 
(area: 6.4 ± 0.8 cm2, perimetro: 9.4 ± 0.8 cm) e per valutare l’allineamento ed il funzionamento della 
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protesi. La maggioranza degli impianti hanno mostrato nessuna o solo minima insufficienza intra- 
(n=104, 93%) e peri-protesica (n=86, 77%) ed un buon funzionamento della protesi (gradiente medio 
4 ± 3 mmHg). Inoltre, all’analisi della velocità delle particelle, le proprietà dei vortici del ventricolo 
sinistro rimangono invariati dopo l’impianto. 
Nei pazienti con IMF severa, 41 (43.6%) con IMF-I e 53 (56.4%) con IMF-nI, l’area massima 3D 
dell’AM (10.7±2.5 cm2 vs 11.6±2.7 cm2, p=0.124) ed a livello del best fit plane (9.9±2.3 cm2 vs 
10.7±2.5 cm2, p=0.135, rispettivamente) sono simili tra i pazienti con IMF-I e IMF-nI. In mesosistole, 
i pazienti con IMF-nI mostrano una maggiore area 3D (9.8±2.3 cm2 vs 10.8±2.7 cm2, p=0.046) e 
perimetro (11.2±1.3 cm vs 11.8±1.5 cm, p=0.048) con lembi più lunghi e grandi, ed un più ampio 
angolo aorto-mitralico (135±10° vs 141±11°, p=0.011). Mentre l’area dell’AM a livello del best fit 
plane non differisce tra i pazienti con IMF-I e IMF-nI (9±1.1 cm2 vs 9.9±1.5 cm2, p=0.063). 
Conclusioni: L’iniziale esperienza pre-clinica della nuova bioprotesi mono-lembo autoespandibile, 
ha evidenziato che l’impianto della valvola tramite approccio TA è fattibile e sicuro con un buon 
risultato emodinamico. L’utilizzo di metodi ecocardiografici avanzati su modello animale è stato 
fattibile ed ha supportato il continuo sviluppo di un nuovo concetto di bioprotesi. I pazienti con IMF 
ad eziologia ischemica e non-ischemica hanno simili dimensioni massime dell’AM; le differenze 
sistoliche nella geometria dell’AM dovrebbero essere prese in considerazioni per l’accurata selezione 
delle protesi. 
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Introduction 
Mitral regurgitation (MR) represents the second most frequent valvular heart disease after aortic valve 
stenosis in Europe.1 Among patients with moderate and severe MR, 30% are affected by functional 
MR (FMR) with a high prevalence of the ischemic etiology2.  
Despite the clinical indication, 49% of patients with MR are denied for surgery due to advanced age, 
reduced ejection fraction and multiple comorbidities3 and among them the vast majority is 
represented by patients with FMR.4 
If left untreated, MR associates with poor prognosis and , progressive left ventricular dysfunction and 
heart failure (HF).5 Severe MR in patients with heart failure is associated with 20% and 50% mortality 
rates at 1-year and 5-year follow-up, respectively.4 
In the last decade, minimally invasive procedures simulating surgical techniques have been developed 
to extend the therapeutic options for this high surgical risk patients and transcatheter mitral valve 
replacement (TMVR) is one of the recent most promising options.6-8  
Mitral valve (MV) geometry quantification is of paramount importance for the success of TMVR, 
and transthoracic (TTE) three-dimensional echocardiography (3DE) is a useful tool to select the 
patients with the highest likelihood of uncomplicated implant.9  
It has been previously reported that MV geometry may be different in ischemic and non-ischemic 
FMR. Indeed, in patient with ischemic MR (IMR), regional wall motion abnormalities and left 
ventricular (LV) remodeling10 are more often associated with asymmetric mitral annulus (MA) 
dilatation.11 Conversely, in non-ischemic MR (nIMR) global LV remodeling leads to symmetric MA 
dilatation.12 Yet, MV geometry in FMR has been mainly compared with organic MR, and only few 
small echocardiographic studies analyzed MV geometry differentiating between IMR and nIMR.11-14 
However, none of them provided MA geometry characterization framed to pre-procedural screening 
for TMVR.9 
 
Epidemiology of mitral regurgitation 
 
Valve heart disease is becoming an increasing public-health problem. Data from the Euro Heart 
Survey showed that among the isolated native left-sided valve diseases, aortic stenosis was the most 
frequent (n=1197, 43.1%) followed by MR (n=877, 31.5%), aortic regurgitation (n=369, 13.3%), and 
mitral stenosis (n=336, 12.1%).1 Large part of this patients was affected by severe valve disease 
(n=809, 67.6% - aortic stenosis; n=546, 67,6% - MR; n=230, 62.3% -aortic regurgitation; n=232, 
69% -mitral stenosis). The most frequent etiology for aortic valve disease was degenerative. In MR, 
degenerative etiology was also most common (61.3%) followed by rheumatic disease (14.2%), then 
ischemic (7.3%); endocarditis was present in 3.5%. Most cases of mitral stenosis were rheumatic in 
origin (85.4%). Overall, the patients with valve heart disease are often elder with a high frequency of 
cardiovascular risk factors and comorbidities. 
Nkomo and colleagues reported data about the burden of valve heart disease in the US population.15 
Among the 11911 echocardiograms in the pooled population-based study, valve heart disease was 
detected in 615 (5.2%, 95% CI 4.8%–5.6%) participants. MR was the most common valve heart 
disease, while mitral stenosis the least frequent. Similar to the Euro Heart survey, the prevalence of 
valve disease rose strikingly with advancing age. (Figure 1)  
 
Figure 1 Prevalence of valve heart diseases by age.15 
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Moreover, survival of participants with valve disease was significantly reduced compared with 
those without disease. (Figure 2) 
 
 
Figure 2 Survival after detection of moderate or severe valve heart disease.15  
 
 
 
Mirabel and colleagues used the Euro Heart Survey data to estimate the actual proportion of 
symptomatic patients with severe MR in whom the decision not to operate was taken.3 Of the 546 
patients with severe MR, 396 were symptomatic but  in only the 51% of them (n=203)  was decided 
to operate. Combined coronary artery bypass grafting occurred in 39 symptomatic patients (29%) 
treated by surgery during the survey period (n=135) and in 15 of the 18 (83%) patients who underwent 
surgery for ischemic MR. Surgery was denied more frequently in older patients, in those with 
congestive HF, reduced left ventricular ejection fraction (LVEF) and with comorbidity. Patients with 
ischemic MR were more often considered for surgery than those with non-ischemic disease, in 
particular degenerative MR. Mirabel and colleagues suggested that coronary disease mostly drove 
the indication to surgery in patients with ischemic MR, since the majority of patients with ischemic 
MR underwent intervention associated with coronary artery bypass grafting. 
The burden of MR in Europe was recently assessed by the EuMiClip (European Registry of mitral 
regurgitation) group.2 From a total of 63463 consecutive echocardiographic studies performed in the 
participant hospitals during the recruitment period (3 months), 24.4% of patients had MR of any 
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degree. (Figure 3) In the subgroup of moderate and severe MR (n=3309), there were 1806 (55.1%) 
patients with primary MR and 1010 (30.1%) patients with secondary MR. A mixed etiology of MR 
was described in 14.1% of the studies. (Figure 4) Degenerative disease was the most common 
etiology of primary MR (59.8%), followed by Barlow disease (14.4%), rheumatic disease (10.1%), 
endocarditis (1.6%), and congenital disease (1.5%). Additionally, ischemic was the most common 
etiology of secondary MR, present in 51.4% of cases while about 31.9% of patients had dilated 
cardiomyopathy. 
 
 
Figure 3 Distribution of patients with mitral regurgitation in the EuMiClip registry. 2 
 
 
 
Figure 4 Prevalence of mitral regurgitation forms. (A) Prevalence in patients with moderate and 
severe mitral regurgitation. (B)Mitral regurgitation forms by gender. 2  
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In the EuMiClip study population, 70% of patients with severe primary MR met the criteria for 
intervention according to current guidelines,16 while in the secondary MR group only 13.1% where 
eligible for isolated surgical correction. Severe left ventricular dysfunction was found in 38.8% of 
patients with significant secondary MR. Furthermore, the proportion of patients aged over 80 years 
old in this group stood at 25.7 %. 
 
 
Current surgical therapeutic options for patients with functional mitral 
regurgitation 
 
In case of organic (primary) MR, open-heart surgical treatment is the  recommended treatment for 
patients with severe symptomatic MR despite optimal HF medical therapy, reduced LVEF, atrial 
fibrillation secondary to MR or pulmonary hypertension (>50mmHg).16 In case of FMR, the optimal 
treatment is more controversial due to the paucity of data and the significant rates (up to 20%) of 
recurrent regurgitation within the first year after surgery.17 Moreover, recurrence of  MR dramatically 
increase the onset of HF, atrial fibrillation, and re-hospitalization.18 Against this background, only 
15% of FMR patients are referred for surgical treatment.19 Surgery is indicated when associated with 
coronary artery bypass graft procedure or in cases when optimal medical therapy and 
resynchronization have no or minimal results in improving the symptomatology and the patient has 
a low surgical risk.16  
Current guidelines,16 however, do not specify whether to repair or replace the mitral valve, because 
conclusive evidence is lacking, without clear superiority of a strategy over the other.18 Clinical studies 
have suggested that valve repair is associated with lower perioperative mortality,20-22 whereas valve 
replacement provides better long-term correction of the regurgitation with a lower risk of 
recurrence.18  
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The Cardiothoracic Surgical Trials Network (CTSN) conducted a multicenter, randomized trial to 
evaluate the relative benefits and risks of mitral-valve repair versus chordal-sparing replacement, with 
or without coronary revascularization, in patients with severe ischemic MR.18 Among the 251 patients 
that underwent randomization, 126 to mitral-valve repair and 125 to mitral-valve replacement, 86.1% 
had a concomitant coronary artery bypass grafting. All patients undergoing mitral-valve repair 
received complete annuloplasty rings. At 12 and 24 months of follow-up left ventricular reverse 
remodeling, assessed by left ventricular end-systolic volume index, and survival were comparable 
between treatment groups. (Figure 5)  
 
 
 
Figure 5 Time-to-Event Cumulative Incidence Curves of Death and Major Adverse Cardiac or 
Cerebrovascular Events (MACCE). (A) Incidences of patients who died in the mitral valve repair 
group and in the mitral valve replacement group at 2 years. The most frequent underlying causes of 
death were multisystem organ failure (20.8%), heart failure (17.0%), and sepsis (13.2%). (B) 
Incidences of the composite endpoint of safety events at 2-year follow-up. MACCE was defined as 
death, stroke, hospitalization for HF, worsening HF heart failure, or mitral valve reintervention.23 
 
 
At 2-year follow-up, the proportion of patients with recurrent moderate or severe MR was 
significantly higher in the repair group than in the replacement group (58.8% vs 3.8%, p<0.001).23 
(Figure 6) The high rate of recurrence of MR in the repair group did not correspond to significant 
variations in the composite end point of major adverse cardiac or cerebrovascular events, in the 
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quality of life, or in the functional status at 12 and 24 months.18,23 However, in the repair group there 
was a significant increase in HF–related adverse events and cardiovascular-cause readmission. On 
the other hand, patients in the repair group who did not experience recurrent mitral regurgitation 
showed significant reverse remodeling and better quality of life.23  
 
 
Figure 6 Cumulative Failure of Mitral-Valve Repair or Replacement. Failure of the intervention 
was defined as death, moderate or severe mitral regurgitation (MR) as seen on transthoracic 
echocardiography, or mitral valve reintervention.23 
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Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
no significant between-group differences in scores 
on the SF-12 physical and mental subscales or in 
the EQ-5D scores. On the Minnesota Living with 
Heart Failure questionnaire (with scores ranging 
from 0 to 105, with higher scores indicating a 
worse quality of life), there was a trend toward 
greater overall improvement in scores among pa-
tients in the replacement group as compared with 
those in the repair group (Fig. 4). At 2 years, the 
mean change in heart-failure symptoms from 
baseline was 20.0 in the repair group versus 27.9 
in the replacement group (P = 0.07). Among all 
patients regardless of treatment assignment, the 
improvement from baseline was 26.6 among 
patients who did not have recurrent mitral re-
gurgitation versus 16.2 among those with recur-
rence (P = 0.04).
Discussion
The results of this 2-year study advance our un-
derstanding of the relative benefits of mitral-
Figure 2. Cumulative Failure of Mitral-Valve Repair or Replacement.
Failure of the intervention was defined as death, moderate or severe mitral regurgitation (MR) as seen on transtho-
racic echocardiography, or mitral-valve reintervention.
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Transcatheter interventional techniques for functional mitral valve regurgitation 
 
Transcatheter repair techniques can be categorized according to the different type of approach24: 1) 
leaflet repair, 2) direct or indirect annuloplasty, 3) chordal implantation. To date, five devices 
designed for MV repair have received the Conformité Européenne (CE) mark approval. Four of them 
are used for FMR treatment, though anatomic and clinical indications are limited to specific subsets 
and the procedure generally does not allow achieving an almost complete reduction of the 
regurgitation in all patients, with >10% of them having at least moderate residual MR.25,26 To 
overcome these limitations and meet the needs of wider applicability and more predictable reduction 
in MR, TMVR has emerged as a new promising therapeutic option. Although, there are important 
challenges to overcome in the development of this new technology due to the complex MV apparatus 
anatomy, the need for large and highly flexible delivery catheters and the wide spectrum of MV 
disease, TMVR represents the new frontier of intervention and advances of recent years were 
substantial. Several prostheses are currently at different stage of investigation and more than 150 
patients have already been implanted in various early feasibility studies. 
 
 
Transcatheter mitral valve repair system 
1) Leaflets repair 
MitraClip 
The MitraClip (Abbott Vascular, Abbott Park, IL, USA) system replicates the Alfieri’s double 
orifice technique for MV repair. (Figure 7) The device is approved in Europe for treatment of FMR27 
and degenerative MR . Current European guidelines consider the MitraClip system as a therapeutic 
option in high or prohibitive surgical risk patients (Recommendation class IIb, Level of evidence C) 
who meet the anatomical criteria of suitability.16 (Table 1) 
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Figure 7 . MitraClip system. (A) Alfieri stitch surgical technique; (B) Delivery catheter of MitraClip 
system; (C) Mitraclip; (D-F) Essential phases of implantation: (D) alignment of the mitraclip, (E) 
double orifice after clip implantation, (F) MitraClip released with leaflets inside.28 
 
Almost a total of 50.000 MitraClip interventions have been performed worldwide and the 
procedure has been extensively reported after the first clinical use, in 2003.29 Using femoral vein 
access, the trans-septal (TS) puncture is performed at the level of fossa ovalis by 24-F steerable guide 
catheter. After the delivery system is introduced in the left atrium (LA), the MitraClip, a two cobalt-
chrome arms device with 4 mm opening width, is aligned perpendicularly to the MV coaptation line 
and moved then into the left ventricle 10 in order to grasp and grip the two edges of the MV leaflets. 
All MitraClip procedures are performed under fluoroscopic and transesophageal echocardiographic 
(TEE) guidance and during general anesthesia. 
After the first release, an improved version of the device, named MitraClip NT, has been 
developed for a deeper leaflet insertion and more stable fixation. Recently, the latest version of the 
device, the MitraClip XTR, was released and its performance is currently investigated in the MitraClip 
EXPAND study (NCT03502811, www.clinicaltrials.gov). In comparison with the MitraClip NT, the 
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newer system has longer clip arms and longer grippers, facilitating the grasping of MV leaflets. 
(Figure 8) 
 
Table 1. Indications for percutaneous edge-to-edge treatment of mitral regurgitation. Adapted 
from Boekstegers et al10.  
 Optimal valve morphology Conditionally suitable valve 
morphology 
Unsuitable valve morphology  
 
 Central pathology in segment 2 Pathology in segment 1 or 3 Perforated mitral valve leaflet or 
cleft 
 No leaflet calcification Mild calcification outside the grip 
zone of the clip system, ring 
calcification, post annuloplasty 
Severe calcification in the grip zone 
Mitral valve opening area >4 cm2 Mitral valve opening area >3 cm2 
with good residual mobility 
Haemodynamically significant mitral 
stenosis (valve area <3 cm2, mean 
gradient ≥5 mm) 
 
Mobile length of the posterior leaflet 
≥10 mm 
Mobile length of the posterior leaflet 
7-<10 mm 
Mobile length of the posterior leaflet 
<7 mm 
Coaptation depth <11 mm Coaptation depth ≥11 mm  
Normal leaflet strength and mobility  Leaflet restriction in systole 
(Carpentier III B)  
Rheumatic leaflet thickening and 
restriction in systole and diastole 
(Carpentier III A) 
Flail width <15 mm and flail gap 
<10 mm 
Flail width >15 mm only with a 
large ring width and the option for 
multiple clips 
Barlow’s syndrome with 
multisegment flail leaflets 
 
  
  
 
Figure 8. MitraClip NTR and XTR 
 
 
Several randomized controlled trial (RCT) and post-marketing registry have been conducted 
in the recent years with the aim of assessing the effectiveness and safety of the MitraClip system. The 
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EVEREST (Endovascular Valve Edge-to-edge REpair Study) phase I, a non-randomized feasibility 
trial, proved that the procedure had acceptable effectiveness and safety at 6-month follow-up.29 The 
EVEREST II study, a multicentre open-label randomized clinical trial comparing the MitraClip 
procedure with MV surgery (repair or replacement) in operable patients,30 showed at 5-year follow-
up a stable MR reduction and LV remodelling after MitraClip application, without significant 
difference in mortality between the two groups.31 However, the net effectiveness resulted to favor the 
surgical arm (44.2% vs 64.3%,p=0.01) because of a higher prevalence of MR grade ≥2 and 
reintervention in the transcatheter group. Device dysfunction with subsequent need for re-intervention 
occurred mainly within the first 6 months.31 Beyond this time period there were no significant 
differences between the two arms in terms of freedom from surgery.31  
The results of the following two more recent trial have been disclosed in the last months: the 
MITRA-FR trial32 (Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary 
Mitral Regurgitation) and the COAPT trial33 (Cardiovascular Outcomes Assessment of the MitraClip 
Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation). Both trials 
were designed to evaluate the clinical efficacy and safety of percutaneous mitral-valve repair in 
addition to medical treatment in patients with heart failure and severe secondary MR compared with 
optimal medical therapy. In the MITRA-FR trial32, a total of 307 patient with severe secondary MR 
were randomized to percutaneous mitral valve repair and optimal medical therapy (n=152, 
intervention group) or optimal medical therapy alone (n=152, control group). At 1-year follow-up, 
the incidence of death or unplanned hospitalization for HF did not significantly differ between the 
two arms.32 (Figure 9) Despite the good procedural success observed, with 76.4% of MitraClip 
patients showing MR regurgitation 0+ to 1+ at the time of hospital discharge, it was not possible to 
confirm sustained results of the transcatheter intervention for the considerable amount of missing 
echocardiographic and clinical data at follow-up. 
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Figure 9. Kaplan–Meier estimates of survival without a primary outcome event of MITRA-FR. 
Shown are estimates of the probability of survival without a primary out-come event (death from any 
cause or unplanned hospitalization for heart failure) in the two trial group.32 
 
In the COAPT trial33 614 patients were enrolled at 78 centers in the United States and Canada 
and randomized in a 1:1 ratio to MitraClip associated with optimal medial therapy (n=302) or optimal 
medial therapy alone (n=312). At 24 months of follow-up, the total number of hospitalizations for 
HF and death from any causes were significantly lower in the device group compared to the control 
group. (Figure 10 and 11)  
 
Figure 10 Repeat hospitalization due to heart failure and death in the COAPT trial. A) Panel A 
shows the 24-month comparison between cumulative incidences in the primary effectiveness endpoint 
of any hospitalization for heart failure. B) Panel B shows the 24-month comparison between 
cumulative incidences in all-cause mortality.33 
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vice implantation are similar to those reported 
in registries,9,11,22 with 76.4% of the patients in the 
intervention group having a mitral regurgitation 
grade of 0+ to 1+ at the time of hospital discharge. 
Unfortunately, substantial amounts of echocar-
diographic data were missing at 12 months, so 
we cannot confirm a durable result of percutane-
ous repair with respect to the reduction of mitral 
regurgitation at 1 year for many of the trial par-
ticipants.
The lack of a clinical benefit of percutaneous 
mitral-valve repair on the primary outcome sug-
gests that the underlying cardiomyopathy might be 
the principal driver of subsequent adverse clinical 
outcomes in patients with secondary mitral regur-
gitation. In this context, secondary mitral regurgi-
tation may be merely a marker of illness severity 
and not a direct contributor to the pathophysiol-
ogy of heart failure.
Another explanation for the lack of clinical 
benefit that we observed could be the fact that 
some of the patients who underwent percutane-
ous mitral-valve repair had incomplete correc-
tion of mitral regurgitation. Although echocar-
diographic data were missing for many of the 
patients, at least 48 patients in the intervention 
group had residual mitral regurgitation of grade 
2+ or higher at 12 months. Residual mitral regur-
gitation has been significantly associated with 
poorer outcomes.24
The lack of clinical benefit in our trial might 
also be related to the severity of illness in our pa-
tient population. Given the high rate of the pri-
Outcome
Intervention 
Group
(N = 152)
Control 
Group
(N = 152)
Hazard Ratio or 
Odds Ratio
(95% CI)* P Value†
Composite primary outcome: death from any 
cause or unplanned hospitalization for 
heart failure at 12 months — no. (%)
83 (54.6) 78 (51.3) 1.16 (0.73–1.84) 0.53
Secondary outcomes‡
Death from any cause 37 (24.3) 34 (22.4) 1.11 (0.69–1.77)
Cardiovascular death 33 (21.7) 31 (20.4) 1.09 (0.67–1.78)
Unplanned hospitalization for heart failure 74 (48.7) 72 (47.4) 1.13 (0.81–1.56)
Major adverse cardiovascular events§ 86 (56.6) 78 (51.3) 1.22 (0.89–1.66)
*  Hazard ratios were calculated with the use of stratified Cox proportional-hazards models. The primary outcome was 
calculated with the use of a logistic-regression model and corresponds to an odds ratio. The 95% confidence intervals 
were not corrected for multiple testing; therefore, these intervals should not be used to infer definitive treatment effects.
†  No P values other than that for the primary outcome are reported because no adjustment was made for multiple testing.
‡  The rates of the components of the composite primary outcome do not total the rates of the composite because pa-
tients could have more than one event.
§  This category is a composite of death, stroke, myocardial infarction, or unplanned hospitalization for heart failure.
 Table 3. Primary Outcome and Secondary Efficacy Outcomes at 12 Months (Intention-to-Treat Population).
Figure 2. Kaplan–Meier Estimates of Survival without a Primary Outcome Event.
Shown are estimates of the probability of survival without a primary out-
come event (death from any cause or unplanned hospitalization for heart 
failure) in the two trial groups (Kaplan–Meier estimates according to indi-
vidual trial outcomes are provided in Fig. S2 in the Supplementary Appendix). 
The number of patients at risk in the intervention group at month 0 was 151 
rather than 152 because 1 patient died before randomization, but trial person-
nel did not become aware of his death until after he was randomly assigned 
to the intervention group.
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The benefits were consistent across several subgroups, including patients who had ischemic 
and non-ischemic cardiomyopathy and were independent of MR grade, LV volume, and LV function 
at baseline. The number needed to treat to prevent 1 hospitalization for heart failure within 24 months 
was 3.1 (95% CI, 1.9 to 7.9); the number needed to treat to save 1 life within 24 months was 5.9 (95% 
CI, 3.9 to 11.7).  
Two main differences could partially explain the opposite results of the two trial: patient’s 
selection and length of follow-up. Despite in both trials were included only patients with severe MR, 
in the COAPT trial severe LV dilatation was an exclusion criterion (LV end-systolic diameter >70 
mm). Moreover, in the COAPT trial the lower mortality became apparent after 1 year after from the 
intervention, which is when the MITRA-FR trial follow-up was terminated. 
 
The three largest published European registries are: the German registry (TRAMI, 
TRAnscatheter Mitral valve Implantation) including 828 patients, the ACCESS-EU (MitraClip 
Therapy Economic and Clinical Outcome Study in Europe) including 567 patients, and the TCVT 
(TransCatheter Valve Treatment) sentinel pilot registry including 628 patients.34,35,36 When compared 
with the EVEREST trial, data from these registries demonstrated a higher procedural success (97%, 
91.%, and 95% in the TRAMI, ACCESS-EU, and TCVT registries respectively compared with 77% 
in the EVEREST II trial) and a lower prevalence of MV reintervention (8.5%, 9.7%, and 3.8% in the 
TRAMI, ACCESS-EU, and TCVT registries respectively compared with 21% in the EVEREST II 
trial). However, there was also a higher incidence of mortality in the observational studies both at 30 
days (4.5% and 3.4% in the TRAMI and ACCESS-EU registries respectively vs 1% in the EVEREST 
II trial) and at 1 year (20.3%, 17.3%, and 15.3% in the TRAMI, ACCESS-EU, and TCVT registries, 
respectively vs 6.1% in the EVEREST II trial)31,34,35,36.  
Several trials testing the MitraClip system are still ongoing. The COAPT CAS — the 
extension of COAPT trial — is focusing on the use of MitraClip NT systems in patients with FMR 
and HF. The MITRA-CRT (MitraClip in Non-Responders to Cardiac Resynchronization Therapy; 
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NCT02592889, www.clinicaltrials.gov) trial has the main objective of comparing the efficacy and 
safety of MitraClip and optimal medical therapy (OMT) versus OMT alone in patients with 
symptomatic FMR without response to CRT. The MATTERHORN (Mitral vAalve reconsTrucTion 
for advancEd Insufficiency of Functional or iscHemic ORigiN; NCT02371512, 
www.clinicaltrials.gov) trial compares the MitraClip intervention vs the reconstructive/replacement 
surgical therapy in patients with FMR associated with LV dysfunction and increased risk for surgery. 
 
2) Annuloplasty devices 
Annuloplasty is the most common surgical repair technique for FMR which aims to reduce 
the MA dimensions. Different devices have been developed to obtain similar objective by using direct 
or indirect - through the coronary sinus - transcatheter approach, but results on MR severity and LV 
reverse remodeling were moderate and heterogeneous. As the MitraClip procedure, most of these 
procedures are performed under fluoroscopic and TEE guidance and during general anesthesia. 
 
A. Direct annuloplasty system 
CardioBand system 
The CardioBand System (Edwards Lifesciences, Irvine, CA, USA) is a dacron band designed 
for supra-annular fixation of the mitral valve. It consists of a flexible incomplete polyester sleeve, 
that is secured to the posterior region of the MA by multiple helix anchors and fixed from the 
anterolateral to posteromedial commissure, and a contraction wire that is connected to the size 
adjustment tool allowing the contraction of the system to cinch the annulus. Transfemoral venous 
access by a 25-F TS steering sheath is demanded for the procedure. (Figure 11) 
The first-in-human CE approval trial included 45 patients with moderate to severe FMR 
(NCT01841554, www.clinicaltrials.gov) showing a technical success rate of 93.6%, with significant 
decrease of the anteroposterior diameter (21.1%, from 36.8±4.8 mm to 29.0 ± 5.5 mm) and MR grade 
≤ 2 in 88%. The CardioBand received CE mark approval in September 2015. There were two in-
 23 
hospital deaths, both adjudicated as unrelated to the device or procedure, one due to hemorrhagic 
stroke and the other one to elective MV replacement and tricuspid annuloplasty intervention for 
device malfunction.37 Among serious adverse events, there were two recurrent MR due to partial 
anchor detachment in the early phase of the study.37 At 6 and 12-month follow up, respectively 86% 
(n=22) and 94% (n=17) of patients showed MR ≤2 and 82% (n=22) and 68% (n=18) had NYHA class 
I-II.38 In August 2016, the REPAIR (transcatheteR rEPair of mitrAl Insufficiency With caRdioband 
System; NCT02703311, www.clinicaltrials.gov) efficacy trial, has started and is currently enrolling 
patients with severe FMR and HF symptoms to test the decrease in MR grade and symptoms 
improvement, as well as to evaluate the safety of the CardioBand system in the post-marketing 
setting. 
 
Figure 11 CardioBand system. (A) CardioBand system before implantation and (B) after 
implantation. The implant is a polyester sleeve with radiopaque markers spaced 8 mm apart. (C) The 
guide catheter delivering the annuloplasty ring in segments. (D) Final annuloplasty ring encircling 
the posterior leaflet. 
 
 24 
AccuCinch system® 
The AccuCinch® System (Ancora Heart, Santa Clara, CA, USA) is the first ventriculoplasty 
device that addresses dilated cardiomyopathy of either ischemic or non-ischemic etiology, aiming to 
obtain reverse LV remodeling and reduction in MR severity. It is made of 12 to 16 self-expandable 
nitinol anchors and 6-7 nitinol force distribution members. The device is implanted through a 
retrograde approach, using a 18-F femoral artery sheath, in the posterior sub-annular LV 
myocardium.39 Anchors are placed to create a 220° arch that surrounds the posterior leaflet of the 
MV. The cinching force applied to the basal LV free wall is transmitted to the MA, reducing its 
dimension. (Figure 12) 
 
 
Figure 12 Delivery of the Accucinch System. The subannular space is accessed using the guide 
catheter and the modular guide tunnel (MGT) positioned over a guidewire (A). The inner and outer 
MGT windows are aligned and anchors delivered (B). The inner MGT window is progressively 
withdrawn and subsequent anchors delivered (C) until the complete number of anchors has been 
delivered, joined by the cinch cable (D). The cinch cable is then progressively tightened to reduce 
the basal left ventricular and mitral annulus dimensions (E). The cinch cable is then locked to 
maintain the tension and cut (F) prior to removal of the guide catheter and MGT.39 
 
There were two studies addressing the feasibility, safety and efficacy of AccuCinch® System, 
involving around 10 patients: LVRECOVER (Left Ventricular Reshaping of the Mitral Apparatus to 
Reduce Functional Mitral Regurgitation and Improve Left Ventricular Function Trial;  
NCT02153892, www.clinicaltrials.gov) and LVRESTORESA (Percutaneous Left Ventricular 
Reshaping to Reduce Functional Mitral Regurgitation and Improve LV Function; NCT01899573, 
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www.clinicaltrial.gov) trials, both with promising results. An expansion of the feasibility study has 
been approved in US and recruitment should start soon.  
 
Mitralign System 
Mitralign Transcatheter Annuloplasty System (Mitralign Inc., Tewksbury, MA, USA) 
replicates the surgical annular plication using a set of devices placed at the level of posterior annulus, 
through the LV. Two pairs of polyester pledgets are delivered at the sites of P1 and P3 and then pulled 
together to decrease the annular circumference. After achieving the desired result, the plication is 
locked.40 (Figure 13). The procedure is performed using a 14-F catheter transfemoral retrograde 
approach under real time 3D and 2D TEE. 
 
 
Figure 13. MITRALIGN System. (A) Bident catheter and wire crossing mitral annulus (B) Pledget 
delivery (C) Pladget plication and lock 
 
The ALIGN study (Mitralign Percutaneous Annuloplasty System for Chronic Functional 
Mitral Valve Regurgitation; NCT01740583, www.clinicaltrials.gov) included 71 patients with FMR 
grade ≥2. Device success rate was 70.4% and no intraprocedural death occurred. Thirty-day (n=45) 
and 6-month (n=41) incidences of all-cause mortality, stroke, and myocardial infarction were 4.4%, 
4.4%, and 0% and 12.2%, 4.9%, and 0% respectively. At 6 months, non-urgent MV surgery was 
performed in 1 patient (2.4%) and non-urgent percutaneous repair in 7 patients (17.1%). The results 
of 6-month follow-up showed overall signs of reverse LV remodeling with reduction in LV end-
diastolic dimension and LV volume, significant reduction of MA dimensions, both anteroposterior 
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and mediolateral diameters, and MR grade with a significant improvement in coaptation length, 
decreased MV tenting area, and improvement in NYHA functional class.41 Following these results, 
the Mitralign received CE mark approval in February 2016 for treatment of FMR. The Mitralign 
system has been also applied for the treatment of functional tricuspid regurgitation  (SCOUT I Early 
Feasibility Study; NCT02574650, www.clinicaltrials.gov; and the SCOUT II CE Mark Study; 
NCT03225612, www.clinicaltrials.gov).42,43  
 
 
B. Indirect annuloplasty system 
 
The coronary sinus (CS) can be a favorable site for the performance of transcatheter MV repair 
because of its easy accessibility and anatomic proximity to MA. However, the distance between MA 
and CS is variable, smaller at the level of anterolateral commissure (distal CS) and larger at the level 
of posteromedial commissure (proximal CS), and increases with MR grade.44 In addition,  an 
anatomical issue to take into account when considering the indirect annuloplasty is the close spatial 
relationship between CS and left circumflex coronary artery with a potential risk of vessel 
compression during the procedure.  
 
The CARILLON® Mitral Contour System® 
Different devices for indirect annuloplasty have been developed with unfavorable results and 
the studies have been stopped at various preclinical or clinical stage. The CARILLON® Mitral 
Contour System® (Cardiac Dimensions, Inc., Kirkland, WA, USA) is the only device that received 
CE mark approval to date. It is composed of two self-expandable nitinol anchors, proximal and distal, 
connected by a curvilinear ribbon and titanium crimp tubes, designed to plicate the tissue next to the 
MV annulus during the deployment process. The device is advanced in the CS until the distal anchor 
approaches the anterior commissure of the MV, where it will be unsheathed and locked. The delivery 
catheter is gently pulled to apply tension on the system and reduce the FMR. The proximal anchor is 
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positioned near the CS ostium and, after coronary angiography confirming uncompromised flow in 
the circumflex artery, the second anchor is deployed and locked. If the coronary angiography shows 
flow compromise in the left coronary artery, the device can be recaptured and repositioned.27 Device  
dimensions and anchor location are chosen by direct measurement of the CS with a calibration 
catheter during venography. There are 37 possible combinations of anchors size and device lengths.45 
The device can be combined with a MitraClip procedure45, and it does not preclude implantation of 
a CS lead for cardiac resynchronization.46 It received CE mark approval in 2011 for the model XE2. 
(Figure 14) 
The first-in-human feasibility study of the CARILLON® Mitral Contour SystemTM —
AMADEUS (Mitral Annuloplasty Device European Union Study) trial— showed at 6-month follow-
up favorable results with a significant reduction of MR and MA diameter, a trend towards reverse 
remodeling of the LV, preserved values of LVEF over time, and a significant improvement in exercise 
tolerance and quality of life.47 The TITAN (Transcatheter Implantation of Carillon Mitral 
Annuloplasty Device) trial48 was a prospective, non-randomized, open-label, multicenter study using 
a slightly improved version of the device: the CARILLON XE2. Compared with baseline, patients 
had a significant and stable reduction of MA mediolateral diameter, MR quantitative parameters and 
LV diameter and volume, along with a significant and sustained improvement up to 24 months in 
NYHA functional class and 6-minute walking test (6MWT). However, there were several cases of 
device wire fracture, though without adverse events or clinical events. To reduce the risk of fracture, 
the device underwent further enhancement in the most recent version — the CARILLON mXE2 — 
which was tested in the TITAN II trial.49 The CARILLON mXE2 was associated with improvements 
in clinical and echocardiographic parameters in patients with FMR, while successfully addressing the 
issue of anchor fracture49. The CARILLON mXE2 was used in the REDUCE FMR (NCT02325830, 
www.clinicaltrials.gov) multicenter, double-blind, randomized clinical trial where symptomatic 
patients with FMR were compared with a randomized control group which is medically managed 
according to HF guidelines, with an estimated enrolment of 400 subjects.50 
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Figure 14 CARILLON® Mitral Contour System. The system is designed to be implanted within the 
coronary sinus (CS) or the great cardiac vein (GCV) to reduce the cross-sectional area of the mitral 
annulus and subsequently to reduce the functional mitral regurgitation (A and B). The procedural 
feasibility and effectiveness of this device depend on the anatomical course of the coronary sinus in 
relation to the mitral annular plane and the circumflex artery (Cx). Multi-detector row computed 
tomography provides three-dimensional visualization of these spatial relationships and enables the 
relative distance between the CS and the mitral annular plane (double arrow) and the Cx (arrow) 
(C)51,52. 
 
 
The ARTOTM system 
The ARTOTM (MVRx Inc., Belmont, California) system is designed to increase leaflets 
coaptation in FMR by reducing the MA anteroposterior diameter by a connecting bridge between 
interatrial septum and CS. It can be considered part of the annuloplasty techniques, but it does not 
share a common approach, so we decided to describe it apart from the annuloplasty devices. Using 
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12-F sheaths, two magnetic catheters are introduced in the right internal jugular vein and right femoral 
vein, respectively. The first catheter is then placed in the CS and the latter in the LA, after the TS 
puncture. The two magnetic tips are linked posteriorly, in the LA, behind the posterior MV leaflet. A 
small puncturing wire is advanced from the CS into the LA to create a continuous loop wire from the 
right internal jugular vein to the ipsilateral femoral vein. A CS anchor is placed and connected to an 
atrial septal anchor by an adjustable suture, so the anteroposterior diameter of the MA can be 
shortened until significant reduction in MR is obtained under TEE guidance. The suture is finally 
locked and the delivery system retrieved.53 (Figure 15) 
 
Figure 15 The Arto System implantation procedure. A) Great cardiac vein (GCV) and left atrial 
(LA) MagneCaths in position and magnetically linked behind the P2 segment of the posterior mitral 
leaflet. B) Close-up of magnetically linked LA and GCV MagneCaths. Each magnetic catheter has a 
specific shape and lumen to direct and receive the crossing wire. C) The crossing wire (arrow) is 
pushed from the GCV into the LA MagneCath. The MagneCaths are aligned to direct the wire safely 
from the GCV to the LA through the atrial wall. D) After using an exchange catheter, the loop 
guidewire is placed across left atrium. This guidewire directs the placement of the GCV anchor (T-
bar) and septal anchor. E) The MVRx System in place before tensioning. T-bar, single arrow; septal 
anchor, double arrow. F) Tensioning of the bridge results in precise shortening of the mitral annulus 
anteroposterior diameter (arrows) and reduction of FMR; once the final position is obtained, the 
suture is cut and secured with a suture lock. 54.  
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The MAVERIC (Mitral Valve Repair Clinical Trial; NCT02302872, www.clinicaltrials.gov) is 
an ongoing first-in-human, multi-center, observational study, enrolling patients with MR grade ≥2 
and HF of any etiology (NYHA functional Class II-IV) who could not undergo MV surgery.53 To 
date, more than 45 patients have been enrolled and 11 of them reached 3-year follow-up. Technical 
success was obtained in all patients and at 30-day follow-up an improvement in MR grade, MA 
anteroposterior diameter, LV dimensions, and NYHA functional class was observed; no deaths, 
myocardial infarction or stroke were reported. At 2-year follow-up, there was a reduction of 64% in 
HF rehospitalization.54 These improvements were sustained from 1 to 3-year follow-up.55,56 
 
3) Chordal implantation  
Among the different surgical strategies, the “respect rather than resect” approach with implantation 
of one or more artificial chords represents an alternative for patients with primary MR.57 Three mini-
invasive devices have been developed to replicate chordal implantation in a beating heart without 
cardiopulmonary bypass: the NeoChord DS100 Delivery System (NeoChord, Inc., Eden Praire, MN, 
USA) and MitraFlexTM (TransCardiac Therapeutics, Atlanta, GA, USA) intended for a transapical 
(TA) approach and the Babic device by a TS route. Among them, only the NeoChord DS100 Delivery 
System (NeoChord, Inc., Eden Praire, MN, USA) is CE marked for the treatment of primary MR 
regardless of the risk profile of the patient. Artificial cords have never been used in patients with 
FMR. 
 
 
 
Transcatheter mitral valve implantation 
 
Important challenges needed to be overcome for the development of the prostheses and make 
feasible the delivery. The MV apparatus anatomy is extremely complex leading to significant delays 
in the implementation of this transcatheter strategy in the clinical practice.58 First, the MA presents 
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close anatomic relationship with the left ventricle outflow tract (LVOT), aortic valve structures, CS 
and circumflex artery which imply a potential risk of compression and damage during or after valve 
replacement.58 Second, the MA shows asymmetrically saddle-shape with large dimensions which 
translates into large prostheses and delivery systems.58 Third, the MA is a dynamic structure which 
does not complies well with rigid devices.58  
The implantation of a MV prosthesis in a native valve, as in the case of FMR, is additionally 
demanding since the landing zone is usually consisting of a dilated MA, with no or minimal 
calcification. Compared with transcatheter aortic valve implantation, the younger age of patients with 
MR, the broadly heterogeneous pattern of MV disease, and the absence of a validated transcatheter 
treatment for the frequently associated significant tricuspid regurgitation produced additional issues 
in the development process of the prostheses. To the best of our knowledge, there are at least 30 
TMVR systems under development and they actually represent only the devices that have reached 
the feasibility study in humans stage. 
 
TIARATM valve system 
The Tiara valve (Neovasc Inc., Richmond, British Columbia, Canada) consists of a nitinol 
self-expanding frame and three leaflets of bovine pericardium. It is D-shaped and characterized by 
an atrial skirt and a ventricular anchoring system for the trigones and the posterior MA that can 
capture the native anterior and posterior leaflets.59 Prosthesis size ranges from 30 to 45 mm. 
Implantation is performed through TA approach, with a 32-F delivery system, by TEE and 
fluoroscopy guidance. When the device is advanced in the LA, the valve is partially unsheathed to 
allow the orientation and alignment of the flat part of the D-shaped prosthesis towards the aorta. Next, 
the device is pulled back to reach the atrio-ventricular groove and subsequently unsheathed to release 
the anchoring system and fully deploy the valve.60 (Figure 16) 
After preclinical evaluation,6 a total of 56 patients with severe FMR and primary MR and high 
surgical risk have been successfully treated with Tiara implantation to date61: 40 patients were 
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enrolled in the TIARA-I feasibility clinical study (NCT02276547, www.clinicaltrials.gov) and 16 
patients were enrolled in the TIARA II CE Mark study (NCT03039855, www.clinicaltrials.gov). 
Paravalvular leaks were reported as absent/trace/mild in 100% of the cases. Four deaths were reported 
30 days after implantation.59,60,62 
 
 
Figure 16 TIARATM valve system63 
 
 
FORTIS valve system 
The FORTIS valve (Edwards Lifesciences, Irvine, CA, USA) is made of a self-expandable 
nitinol frame, three symmetric bovine leaflets, an atrial flange, and two opposing paddles that capture 
the native leaflets and secure them. (Figure 17) The only available size is 29 mm and the implantation 
is performed through apical access via a 42-F delivery system, under TEE and fluoroscopy guidance. 
After the valve is advanced in the mid-LV cavity, the paddles are partially unsheathed and oriented 
to engage the A2-P2 scallops, and then are fully exposed. The device is later advanced in the LA and 
the atrial flange is released first, followed by the valve.64,65 
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Figure 17 FORTIS transcatheter mitral valve. A) Side profile of the FORTIS valve highlighting the 
atrial flange (red arrow), body of the FORTIS valve (black arrow) and one of the two paddles (blue 
arrow). B) Side profile of the FORTIS valve highlighting the bovine pericardial leaflets (orange 
arrow) and the flexible struts (green arrows), which align with the A2 segment of the mitral valve.65 
 
Bapat et al.66 reported the results of 13 patients, among the 20 that received Fortis valve for 
compassionate use or in the context of the feasibility study. All the patients fulfilled the anatomical 
criteria for the only available size (29 mm).65 Procedural success was obtained in 76.8% of patients 
(10/13) with 2 conversions to conventional heart surgery. In-hospital and 30-day mortality were 
30.8% (4/13) and 38.5% (5/13) respectively. The echocardiographic assessment confirmed the good 
function of the prosthesis at discharge.66 Two patients died during the 2-year follow-up due to 
terminal HF, leading to an all-cause mortality rate of 54%. Sustained MR reduction was documented 
at 2-year follow-up.64 In May 2015, Edwards Lifesciences temporally paused the Fortis valve 
program for a thrombotic issue. In August 2015, the company acquired the CardiaAQ (Valve 
Technologies Inc., Irvine, CA, USA). 
 
 
CardiaAQTM valve system  
The CardiAQ valve system (Edwards Lifesciences, Irvine, CA, USA) is composed by a self-
expandable nitinol frame with three bovine tissue leaflets, designed for both TA and TS access, by 
using two different delivery systems (33-F). The device has an inflow and an annular part (30 and 40 
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mm diameters respectively), designed for MA dimensions ranging between 36 and 39.5 mm. The 
valve is symmetric, characteristic that overcome orientation issues, and equipped with two sets of 
opposing anchors: the LV anchors, covered by polyurethane foams to reduce tissue injury and 
designed to engage the leaflets and the sub-valvular apparatus, and the LA anchors which ensures 
axial stability. The frame is covered by a polyester fabric skirt to reduce the possible leaks.67,68 
(Figure 18) Regardless of the access route, before navigation of delivery catheter in the LV, the wire 
pathway is checked for impingement of the mitral sub-valvular apparatus (Copenhagen maneuver) 
using a 46 mm Reliant balloon catheter (Medtronic, Mineapolis, MN, USA). When CardiAQ is 
centrally positioned at the level of the MV plane, LV anchors are flipped and the device is 
progressively expanded to capture both leaflets. Once MV leaflets catching is confirmed by TEE, the 
LA anchors are exposed and the device is completely deployed in a supra-annular/intra-annular 
position to avoid LVOT obstruction.67,68 
Early results from compassionate implantation of the 2nd generation of the CardiAQ (three 
TA69 and one TS implantation67) demonstrated that both approaches are feasible and effective. The 
early feasibility study using TS delivery system is ongoing in the United States (NCT02718001, 
www.clicaltrials.gov) and it is estimated to enroll a total of 30 patients with MR grade ≥2 and high 
risk for conventional surgery. 
 
 
Figure 18 CardiAQTM valve system70 
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TENDYNE valve system 
The Tendyne valve (Abbott Vascular, Abbott Park, IL, USA) is designed for both FMR and 
primary MR and consists of two self-expandable nitinol frames – a D-shaped outer frame and a 
circular inner frame - with three porcine pericardium leaflets and an epicardial pad.71 (Figure 19) 
Valve implantation is performed under fluoroscopy and TEE guidance using a TA delivery sheath 
(34-F) that is inserted perpendicularly to the MV plane. The wire path is checked with a balloon-
tipped catheter. After introducing the prosthesis in the LA and having partially deployed it, the 
orientation of the frame is checked so that the flat part of the D-shaped outer frame is placed against 
the mitro-aortic continuity. The device is therefore retracted to land in the MV groove for the 
complete deployement. The last step is the insertion of the epicardial pad and the adjustment of the 
tether tension.71,72 
 
Figure 19 TENDYNE Valve System73 
 
In 2014 Lutter et al.8 reported the results of an acute human study, in which prostheses were 
implanted and observed for 2 hours in 2 patients with primary MR before conventional MV surgical 
replacement, that showed the feasibility of the TA approach with reduction of the MR grade. The 
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first-in-human experience with three compassionate implantations (two FMR) confirmed the 
feasibility and the acute success of the procedure.72 The ongoing global feasibility trial 
(NCT02321514, www.clinicaltrials.gov) is enrolling high surgical risk patients with severe FMR and 
primary MR who are not suitable for conventional MV repair or replacement.74,75 A total of 350 
subjects at more than 40 centers is planned to be enrolled in the study. Muller et al. reported the 
overall experience in 30 patients (23 with secondary MR) until March 2016, with a successful 
implantation in 28 (93.3%) of them. There were no acute deaths, strokes or myocardial infarctions. 
At 30-day follow-up, MR was absent in 26 patients and trivial in one case. Significant LV remodelling 
was observed in all cases. 
 
 
 
 
INTREPID valve system 
The Intrepid TMVR system (Medtronic, Minneapolis, MN, USA) has two interconnected self-
expandable nitinol stents - a circular 27-mm inner stent and an outer fixation ring with three available 
sizes of 43, 46 and 50 mm - with three bovine pericardial tissue leaflets and a flexible brim. (Figure 
20) The outer ring is designed to conform the MV dynamic anatomy without distortion of the inner 
stent and the leaflets and is intended to be fixed to the MA by the radial force. The procedure is 
performed through TA approach, under TEE and fluoroscopy guidance. Once delivery catheter is 
coaxial with the MV and the system is advanced into the LA, the valve is oriented to align the support 
arms to the A2-P2 scallops and then expanded until the brim is completely deployed. The catheter is 
subsequently retracted in the atrio-ventricular groove and the fixation ring is also expanded until the 
valve is completely released. The Intrepid TMVR system does not require rotational alignment or 
capturing of the MV leaflets.76 
The Twelve Intrepid TMVR Pilot Study (Evaluation of the Safety and Performance of the 
Twelve Intrepid Transcatheter Mitral Valve Replacement System in High Risk Patients with Severe, 
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Symptomatic Mitral Regurgitation; NCT02322840, www.clinicaltrials.gov), including 50 patients 
with severe MR (84% with FMR) and high risk for conservative MV surgery, showed successful 
implantation in 48 cases. One patient had bleeding during the apical access and there was one failure 
of implantation due to sizing miscalculation and mispositioning of the valve. At 30-day follow-up, 7 
deaths were reported and 5 patients needed reoperation due to access site bleeding. However, 
significant reduction in MR was observed in all alive patients and mild or no symptoms were reported 
in 79% of cases.7  
 
 
Figure 20 INTREPID valve70 
 
 
The APOLLO trial (Transcatheter Mitral Valve Replacement with the Medtronic Intrepid 
TMVR System in Patients with Severe Symptomatic Mitral Regurgitation Study; NCT03242642, 
www.clinicaltrials.gov) will consists of a cohort of about 650 patients amenable to conventional 
open-heart MV replacement, randomly assigned to either Intrepid or surgery, and a single arm cohort 
of about 550 patients with high risk for conventional MV surgery undergoing TMVR procedure with 
the Intrepid TMVR system. 
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HighLife valve system 
The HighLife mitral valve (HighLife Inc., Paris, France) system has two components, a 31-
mm sub-annular implant and a nitinol self-extendable frame with three leaflets of bovine pericardium, 
together creating a “valve-in-ring” implantation.77 The prosthesis is available only in a single size. Its 
shape has a preformed groove in the annular region so that it fits the sub-annular locking component.78 
The prosthesis can be deployed both through TA and TS access, while the locking component is 
implanted in the sub-valvular apparatus by retrograde approach via femoral artery. When the valve 
delivery catheter crosses the native MV and sub-annular implant, the valve is partially deployed in 
the LV and subsequently moved to reach MV ring. The final step is the complete deployment in the 
LA.78 (Figure 21)  
 
 
Figure 21 HIGHLIFE valve implantation. (A-B) The catheter for the loop placement (LPC) is 
advanced using a retrograde approach through the aortic valve. A guidewire loop is placed and both 
ends externalized. The delivery and closure of the sub-annular implant (SAI) are carried out with a 
dedicated 18 Fr delivery catheter (SDC) hosting the SAI and the two ends of the previously placed 
guidewire loop. (C) The TMV delivery catheter is inserted through either the transapical (shown 
above) or the transatrial access. The outflow end of the TMV is deployed distal from the SAI and the 
SAI positioned close to the native annulus. (D) Then, the inflow end of the TMV is deployed by the 
delivery catheter.78 
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A preclinical study showed the safety of the procedure and the histological examination from 
chronic models revealed tissue growth around the sub-annular ring with subsequent stabilization of 
the implant and leak prevention.78 The first-in-human experience with two compassionate 
implantations was reported in August 2017. Both valves were implanted through apical access and 
no intraoperative complications were reported. The echocardiographic assessment showed excellent 
prosthetic valve function with only mild intra-prosthetic regurgitation. One patient survived and the 
5-month follow-up showed excellent prosthesis performance. The second patient died after 4 days, 
despite a technically successful procedure, probably because of LV overload. A multi-center 
feasibility study is ongoing (NCT02974881, www.clinicaltrials.gov) and recruiting patients with 
severe MR, unsuitable for surgical treatment. 
 
 
AccuFit valve system 
The AccuFit system (Sino Medical Sciences Technology Inc., Tianjin, China) is composed of 
a self-expandable nitinol frame with three bovine pericardial leaflets, equipped with a supra-annular 
fixation and mitral-clipping anchoring mechanism.79 The frame is divided into an atrial and a 
ventricular flange and the annular support is composed of a row of anchoring clips to secure the native 
valve. The clipping area is covered with a skirt, which is in continuity with the atrial flange in order 
to avoid paravalvular leaks. (Figure 22) The initial reverse design of the leaflets, with a central 
diastolic opposition and a circumferential coaptation, was abandoned in favor of the current 
conventional prosthesis design.79,80 Currently available size range is 30-42 mm, with 4 mm 
increments. Valve protrusion in the LV is less than 14 mm to avoid the LVOT interaction. Procedure 
is performed through TA approach, using a 38-F delivery catheter, under TEE and fluoroscopy 
guidance. The delivery requires 4 steps: (1) device unsheathing and localization at the MV annulus 
plane; (2) ventricular flange advancing to entrap MV leaflets; (3) atrial flange release to clipping 
annulus and (4) complete deployment of the prosthesis.81 A preclinical study demonstrated the safety 
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of the procedure, with minimal paravalvular leakage and LVOT obstruction.80,81 A D-shaped atrial 
flange is under evaluation.81 
 
 
Figure 22 The AccuFit™ TMVR prosthesis. The atrial aspect (left, lower) and the ventricular aspect 
(right, lower) displaying the reverse leaflet design80 
 
 
Caisson valve system 
The Caisson TMVR system (LivaNova PLC, London, England) is a two-component device, 
consisting of an anchor and a three-leaflet porcine pericardial valve. The anchor is a D-shaped self-
expanding nitinol structure that serves as foundation for the valve and grips the native MV. (Figure 
23) The prothesis is delivered through transfemoral approach, using a 31-F delivery system.82 The 
first-in-human implants were successfully performed in the United States in 2016.83 An ongoing 
feasibility study - the PRELUDE (Percutaneous mitral valve replacement evaluation utilizing the 
investigational device exemption early feasibility study; NCT02768402, www.clinicaltrials.gov), 
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with an estimated final enrolment of 20 subjects, is currently recruiting patients, but no data is 
available so far. 
 
Figure 23 Caisson Valve. (A) Valve prosthesis. (B) Fluoroscopy. (C) Two-dimensional 
transesophageal echocardiography.84 
 
 
MValve system 
The MValve docking device (Boston Scientific Corporation, Marlborough, MA, US) is not a 
valve per se, but a support platform that can be anchored within the mitral annulus, enabling the 
implantation of an approved transcatheter valve prosthesis. The first-in-human experience was 
performed in September 2015, in a patient with rheumatic valve disease, with no major periprocedural 
complications.85 The feasibility study (NCT02719912, www.clinicaltrials.gov) will evaluate the 
MValve device in conjunction with the LOTUS system (Boston Scientific Corporation, Marlborough, 
MA, US) in high risk patients, with severe primary MR and FMR. The company is currently working 
on the design of the next generation of MValve and the recruitment status is unknown so far. 
 
 
 
Current challenges of transchateter mitral valve replacement 
 
 Although epidemiological data underline the unmet clinical need of optimal therapeutic 
approach for secondary MR, it has been reported an elevated screening failure among patients 
candidate to new transcatheter intervention mainly due to clinical and anatomical factors (e.g. >70% 
in the Intrepid Global Pilot Study).86 Moreover, several complications associated with TMVR have 
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been described across the feasibility studies. Smaller-size delivery catheters with very high flexibility 
and prostheses with favourable profile are required to reach the MV through a TS access and actually 
most of the available systems do not satisfy such requirements and need a mandatory more invasive 
TA approach. The complex three-dimensional anatomy and the high-pressure gradient generated by 
the LV during systole contribute to the frequent occurrence of paravalvular leakage and several 
technical improvements were made during recent years to overcome these issues. Considering the 
significant geometrical LV abnormalities in patients with FMR, the development of a prosthesis with 
optimal adherence to the MA is extremely challenging. In the FMR subset, the MA usually has low-
grade or no calcifications making the anchoring of the valve more unstable. The radial stiffness of 
the prosthesis needs to be carefully optimized to get enough strength to avoid the fracture of the frame 
over time and enough flexibility to avoid the perforation of adjacent structures without increasing the 
risk of displacement or embolization.87 LVOT obstruction has been described after surgical MV 
procedures88, valve-in-valve or valve-in-ring89,90 interventions and TMVR shares this potential 
complication too. TMVR systems that are not designed to capture the native MV leaflets are more 
prone to bulking into the LVOT.91 Multiple risk factors should be evaluated when assessing the risk 
of LVOT obstruction with TMVR procedure: (1) an acute aorto-mitral annular angle (the angle 
between the annular planes of the two valves); (2) septal hypertrophy in the basal segment; (3) valve 
protrusion in the LV.92 (Figure 24) Iatrogenic atrial septal defect is a common complication after TS 
approach and it can be associated with right-sided heart enlargement, worsening of the tricuspid 
regurgitation and higher re-hospitalization rates for HF. The further improvements in available 
technology or the development of novel systems will help in overcoming most of the issues identified 
during and following TMVR procedure. 
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Figure 24 Risk factors for LVOT obstruction during a valve-in-valve transcatheter mitral valve 
implantation. THV: transcatheter heart valve90  
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Anterior mitral leaflet laceration in TMVI
Our patient remained haemodynamically stable during the pro-
cedure, made an uncomplicated recovery, and was discharged on 
postoperative day three.
Discussion
Together with the support of operators experienced in LAMPOON, 
procedure planning and equipment selection are key to a successful 
outcome. Accurate positioning of the posterior curve JL 3.5 guide 
catheter in the LVOT at the base of the AML during leaflet puncture 
is challenging as a result of catheter instability and the requirement 
to confirm angiographic positioning in orthogonal views. Prior to 
laceration of the AML, care should be taken to avoid excessive ten-
sion on the encircling wire loop as this may result in severe mitral 
regurgitation and haemodynamic compromise.
Limitations
The current complexity of the procedure means that LAMPOON 
is best performed at centres with high-volume TAVI experience.
Conclusion
Increasing experience with TMVI has led to an improved under-
standing of the mechanics of LVOT obstruction; however, as 
a result, a proportion of patients who stand to benefit from TMVI 
may be declined this treatment due to an excessive risk of LVOT 
obstruction. LAMPOON represents a novel strategy – supported 
by promising early safety outcomes – to minimise the risk of 
LVOT obstruction for selected patients undergoing TMVI.
Impact on daily practice
LAMPOON is a minimally invasive solution for patients other-
wise at prohibitive risk of LVOT obstruction during TMVI.
Conflict of interest statement
M. Kasel and A. Frangieh are proctors and consultants for 
Edwards Lifesciences. A. Greenbaum serves as a proctor for 
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Figure 1. Risk factors for LVOT obstruction during TMVI and the principle of the LAMPOON procedure. A) The primary factors that increase 
the risk of LVOT obstruction during TMVI. B) - D) The principle of the LAMPOON technique. An illustration of the base of the heart, with the 
mitral valve and LVOT viewed from above, is shown. Before intervention the LVOT (dotted red line) is widely patent during diastole (B). 
The struts of the implanted THV cause anterior displacement of the AML, and coverage of the open part of the THV frame, resulting in 
markedly reduced dimensions of the neo-LVOT (a CT-predicted neo-LVOT area of <189.4 mm² suggests a very high risk of subsequent LVOT 
obstruction) (C). Midline laceration of the AML from base to tip (dashed blue line) prior to valve implantation can reduce the risk of LVOT 
obstruction. The leaflets of the lacerated AML are displaced laterally by the papillary muscles, improving LVOT area through the THV frame 
after deployment (D).
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Experimental section  
The research project consists of three sub-studies:  
1) Preclinical study assessing the feasibility and early safety of a novel mitral valve self-expandable 
prosthesis 
 2) Evaluation of the prosthesis function by hemodynamic surrogate parameters and blood flow 
characteristics 
 3) Assessment of the mitral valve anatomy using three-dimensional echocardiography in patients 
with functional mitral valve regurgitation focusing on the anatomical implications for prosthesis-
based transcatheter approach 
 
1. Preclinical study assessing the feasibility and early safety of a novel mitral 
valve self-expandable prosthesis 
 
The Epygon transcatheter mitral valve system (EPYGON s.a.s., Affluent Medical, Paris, France) is a 
self-expandable D-shape bioprosthesis consisting of an asymmetric stent  and an advanced bovine 
pericardium tissue mono-leaflet. The asymmetric nitinol stent, with a shorter anterior part, was 
designed to minimize the risk of LVOT obstruction and at the same time reduce the interference with 
the LV wall. The advanced mono-leaflet replicates the physiological diastolic asymmetric flow inside 
the LV. The bioprosthesis has engagement bodies to maintain the traction over the papillary muscle 
preventing the development of LV sphericity after implantation and an anterior arm that captures and 
blocks the anterior leaflet preventing the LVOT obstruction after implantation. (Figure 25-27) 
Available sizes of the Epygon prosthesis are 34 mm, 36 mm and 38 mm according to the commissural 
diameter. 
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Figure 25 Epygon valve from lateral prospective 
 
 
 
 
Figure 26 Epygon valve form posterior prospective 
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Figure 27 Ex-vivo and in-vivo implants of Epygon valve. (A) Ex-vivo implant of the Epygon valve 
in a human heart. (B) In-vivo implant of the Epygon valve in a sheep heart at 5 months. In both 
figures, the anterior arm of the prosthesis captures the anterior leaflet of the mitral valve and 
maintains the traction over the papillary muscle preventing the future development of LV sphericity. 
 
The implantation of the Epygon valve is performed through TA approach, during echocardiographic 
and fluoroscopy guidance. TA implantation of the Epygon bioprosthesis in the preclinical stage of 
the development was performed by a multidisciplinary team including a cardiac surgeon, a 
veterinarian specialized in transcatheter procedures and an echocardiographer, through a small sub-
xyphoid incision and under general anesthesia. When the device is advanced into the LA, the valve 
is partially unsheathed to allow the orientation and alignment of the flat part of the D-shaped 
prosthesis towards the aorta. Subsequently, the device is pulled back to reach the atrio-ventricular 
groove and then unsheathed to release the anchoring system and fully deploy the valve. 
 
The preclinical development of the bioprosthesis was conducted at the Institut Mutualiste Montsouris 
Resercher, Paris. From May 2015 to August 2018, the prototypes of the Epygon valve were implanted 
under echocardiography guidance in 112 small (50 ± 6 Kg) healthy sheep using both the Ta and TA 
access. The sheep were selected according to MA dimension at transthoracic echo (TTE, first 53 
animals) and Multi Slice Computed Tomography (MSCT, last 59 animals). MSCT reconstruction 
allowed also the definition of the access site for the trans-apical approach. (Figure 28) 
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Figure 28 3D reconstruction of a sheep’s heart. Identification of site for puncture and mitral annulus 
measurement with a dedicated software (3Mensio, Pie Medical Imaging, the Netherlands). 
 
Before implantation, after thoracotomy, it was possible to acquire two- and three-dimensional 
transepicardial echo (TPE) from the left ventricular apex by using a transthoracic 4V probe or from 
the roof of the left atrium by using a transesophageal 6T probe. 3D data were post-processed to obtain 
MA dimensions. (Figure 29, Table 2) 
 
Figure 29 Mitral annulus study during the end-diastolic phase in a sheep model. 1: Antero-
posterior diameter; 2: Anterolateral-posteromedial; 3: Area and perimeter of mitral annulus; 4: 
Intertrigonal distance. 
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Table 2 Mitral annulus dimensions in mid-systole and early-diastole in 112 sheep. 
 Diastole Systole 
Antero-posterior diameter (mm) 23 ± 2.6 20.9 ± 4 
Commissural diameter (mm) 32.3 ± 2.6 31.3 ± 4.1 
Perimeter (mm) 9.4 ± 0.8 9.1 ± 1.4 
Area (cm2) 6.4 ± 0.8 6 ± 1.1 
 
During the first 10 sessions, both TA and Ta approach were tested. Later, TA implantation was 
selected as the best option and further improvements of both the prosthesis and the delivery catheter 
were made considering this access route. The first 20 implantations were guided only by angiography. 
TEE was also tested but it was abandoned due to absence of adequate acoustic window in the sheep 
model. Subsequently, intra-cardiac echo and a TEE probe in contact with pericardium to get 
advantage of its higher frequency, were combined and systematically applied to confirm the correct 
orientation and positioning of the valve. The stabilization of the TEE probe upon the roof of the left 
atrium did not interfere with delivery system (Figure 30) and generated “humanized” images. 
(Figure 31) In the last 54 sessions, the intra-cardiac echo and TEE-TPE contributed to the substantial 
improvement in the rates of successful implantation (>90%). 
 
Figure 30 Fluoroscopy image of the transesophageal 6T echo probe placed upon the roof of the 
left atrium. 
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Figure 31 Humanized image obtained by transesophageal 6T echo probe placed upon the roof of 
the left atrium. Multiplanar view during trans-apical puncture. 
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2.  Evaluation of the prosthesis function by hemodynamic surrogate 
parameters and blood flow characteristics 
 
 
After implantation, the performance of the prosthesis was evaluated by using Doppler quantification, 
to assess trans-valvular gradient, intra- and peri-prosthetic leaks, and LVOT obstruction, and both 2D 
and 3D echocardiography, to analyze prosthesis orientation and functioning of anchoring system. In 
the vast majority of procedures there was none or trivial intra- (n=104, 93%) and peri-prosthesis leak 
(n=86, 77%) with good prosthesis function (mean gradient 4±3 mmHg); only one case of LVOT 
obstruction occurred due to prosthesis embolization during the first procedures. (Table 3)  
 
Table 3 Doppler parameters after implantation of Epygon valve 
 Mean ± DS/ N (%) 
Mean gradient (mmHg) 4 ± 3 
Periprosthetic leak 
None 
Trivial 
Mild  
Moderate 
Severe  
 
66 (59%) 
20 (18%) 
24 (21%) 
2 (2%) 
0  
Intraprosthetic leak 
None 
Trivial 
Mild  
Moderate 
Severe  
 
96 (86%) 
8 (7%) 
8 (7%) 
0 
0  
Left ventricular out flow tract obstruction 1 
 
The impact of valve design on intraventricular flow dynamic was also studied using particle imaging 
velocimetry (EchoPIV). Two-dimensional harmonic imaging seeded with ultrasound microbubbles 
contrast agents was used. Swirling intracardiac flow motion is tracked by bubbles and then processed 
by dedicated software (Hyperflow). (Figure 32)  
A preliminary analysis on 14 sheep seems to support the concept that the Epygon bioprosthesis 
respects the normal LV vortex properties of blood both in terms of dimension and orientation. Despite 
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vortex intensity decreased compared with the baseline, the anti-clockwise rotation was preserved 
(positive value of vortex intensity). (Table 4, figure 32) 
Among the different LV energy properties, we found a significant 24.8% increase in energy 
dissipation (energy loss) after device implantation. 
Flow force angle (FFA) reflects the dominant direction of blood flow momentum, that is 0° when the 
flow force is parallel with the LV long axis and 90° when the flow force is transversal; accordingly, 
a lower FFA would reflect a more efficient blood flow dynamic within the LV. After implantation, 
despite mean FFA significantly increased from 30° to 36°, the main axis of the flow roughly remained 
parallel to LV axis. (Figure 32) This finding may be partially explained by the presence of the suture 
stiches after trans-apical access closure that did not allow to place the probe in the same point before 
and after intervention with slight variation in the orientation of the LV long axis.  
 
 
Figure 32 Example of the distribution of dominant flow force angle before and after implantation 
of the Epygon prosthesis. The red triangles are histograms that illustrate both direction and 
amplitude of the left ventricular energy before (left panel) and after (right panel) prosthesis 
implantation. After the procedure (right panel), hemodynamic forces were parallel to the left 
ventricular axis. 
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Table 4 Intra-cavity flow properties before and after implantation  
 Before Implantation After Implantation p 
Vortex Properties 
Area 0.21 ± 0.05 0.20 ± 0.07 0.067 
Intensity 0.38 [0.32; 0.40] 0.29 [0.26; 0.35] 0.019 
Depth 0.35 ± 0.09 0.28 ± 0.87 0.077 
Length 0.59 ±0.16 0.49 ± 0.13 0.091 
Energy Properties 
Energy dissipation 0.79 [0.65; 1.00] 1.14 [0.95; 1.37] 0.009 
Vorticity fluctuation 0.80 ± 0.08 0.90 ± 0.03 0.001 
Kinetic energy fluctuation 1.30 ± 0.27 1.66 ± 0.12 0.001 
Shear stress fluctuation -0.10 [-0.14; 0.17] -0.38 [-0.22; 0.54) 0.110 
Flow Force Properties 
Flow force angle (°) 30.2 ± 4.1 36.5 ± 5.1 0.002 
Flow force dispersion angle (°) 43.4 [40.5; 53.7] 45.6 [43.2; 48.7] 0.778 
Continuous variables distribution was tested by Kolmogorov-Smirnov test and accordingly displayed 
as mean ± standard deviation and compared by paired t test or median [25°; 75° percentile] and 
compared by Wilcoxon rank-signed test. 
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3. Assessment of the mitral valve anatomy using three-dimensional 
echocardiography in patients with functional mitral valve regurgitation focusing 
on the anatomical implications for prosthesis-based transcatheter approach  
 
Mitral valve geometry quantification is of paramount importance for the success of TMVR, and 
transthoracic (TTE) three-dimensional echocardiography (3DE) represents a useful tool to select the 
patients with the highest likelihood of uncomplicated implant.9 It has been previously reported that 
MV geometry may be different in ischemic and non-ischemic FMR. In patient with ischemic MR 
(IMR), regional wall motion abnormalities and left ventricular remodeling10 are more often associated 
with mitral annulus (MA) asymmetric dilatation.11 Conversely, in non-ischemic MR (nIMR) global 
LV remodeling leads to symmetric MA dilatation.12 Yet, MV geometry in FMR has been mainly 
compared to organic MR, and only few small echocardiographic studies analyzed MV geometry 
differentiating between IMR and nIMR.11-14 However, none of them provided MA geometry 
characterization framed to pre-procedural screening for TMVR.9 
The aim of this study was to asses MV geometry in patients with FMR that would potentially benefit 
from TMVR, focusing on the comparison of MA geometry between IMR and nIMR patients in two 
key moments of the cardiac cycle —mid-systole and early-diastole.  
 
 
Methods 
 
Study population  
 
Using the electronical database of the echocardiography laboratory of the department of Cardiac, 
Thoracic and Vascular Science of University of Padua, 94 patients with severe FMR and complete 
transthoracic echocardiography performed between November 2010 and March 2018, have been 
retrospectively selected. Inclusion criteria were: age > 18 years; severe FMR according to the 
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recommended multiparametric approach 93; availability of good quality 3D data sets of both the left 
ventricle (LV) and the MV. We excluded patients with organic MR, mitral stenosis, aortic stenosis, 
more than moderate aortic regurgitation, or those with valve prostheses. Each patient was assigned to 
the IMR or nIMR subgroup according to his/her clinical history and the documentation of 
presence/absence of significant coronary artery diseases. The study was approved by the University 
of Padua Ethics Committee (protocol no. 70299). 
 
Mitral valve analysis software package validation 
 
Two sub-studies were carried on to validate the software package used to quantitate MV geometry 
(4D Auto MVQ, GE Vingmed Ultrasound AS, Horten, Norway). First, the same operator (P.A.) 
performed the quantitative analysis of the MV in a blinded fashion, and after a time interval of one 
month form each other, using the same TTE data sets and both the new and a previously validated94,95 
(4D MV Analysis; TomTec Imaging Systems, Unterschleissheim, Germany) software packages. 
Second, 3D TTE and transesophageal (TEE) echocardiographic MV data sets were analyzed using 
the same software package for MV quantitative analysis (4D Auto MVQ, GE Vingmed Ultrasound 
AS, Horten, Norway) by the same operator (P.A.) in a blinded fashion, after a time interval of one 
week. 
 
Echocardiography and quantitative image analysis 
 
All transthoracic examinations were performed using a commercially available Vivid E9 system (GE 
Vingmed Ultrasound AS, Horten, Norway) equipped with a 4V probe for 3DE acquisitions according 
to a standardized protocol. Image analysis was performed on a dedicated workstation equipped with 
a commercially available software package for offline analysis of 3D datasets (EchoPac 2.02). 
Quantification of LV volume and ejection fraction (LVEF) was performed using 4D Auto-LVQ 
software96 (GE Vingmed Ultrasound AS, Horten, Norway). Left atrium (LA) maximum volume was 
measured using the biplane disk summation method, at LV end-systole.97 MR severity and 
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conventional MV geometry parameters —antero-posterior (AP) and commissural (CC) diameters, 
tenting height and tenting area— were assessed according to current recommendations.93 3D MA 
analysis was performed on dedicated datasets by a single experienced observer (P.A.), using a new, 
commercially available, software package (4D Auto MVQ, GE Vingmed Ultrasound AS, Horten, 
Norway), in two moments of the cardiac cycle: early-diastole and mid-systole. Firstly, two time points 
were identified in the way that the selected frame of the analysis was midway among them. For mid-
systolic analysis, the two time-points were early-systole (the frame after MV closure) and end-systole 
(the frame before MV begins to open). For early diastolic analysis, after identification of early-
diastolic frame (first frame when MV start to open), the two time-points were placed 8 frames before 
and after the selected early-diastolic frame. The two orthogonal planes were adjusted to visualize the 
commissural and longitudinal view of MV (the longitudinal plane intersected the MV at the level of 
A2 and P2 scallops). For initialization, anatomic landmarks have to be added at the level of MA in 
the longitudinal view (posterior, P; anterior, A; leaflets coaptation point, Coap; and aortic valve, Ao) 
and commissural view (MA1 and MA2). The software package automatically created a 3D model of 
the MV in the selected frame which could eventually edited manually, if needed. (Figure 33) 
Quantitative parameters of the MV geometry, provided automatically, were: MA 3D area; MA 2D 
area (projected 2D area at the level of the best fit plane); MA perimeter; MA AP diameter, as the 
distance between the two landmarks A and P; MA anterolateral-posteromedial diameter (ALPM), as 
the longest diameter of MA perpendicular to AP diameter; sphericity index (as the ratio between AP 
and ALPM diameters); MA CC diameter, as the distance between the two commissure; MA inter-
trigonal distance, measured between the two automatically identified trigons; MA height, as the 
distance between the lowest and the highest points of MA; the non-planimetry angle, that assesses 
the saddle shape of MA; mitral-aortic angle, as the angle between the aortic valve and the MA (along 
the AP direction) planes; anterior and posterior leaflets area and length, MV tenting height, tenting 
area and tenting volume.  
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Figure 33 Mitral annulus parameters automatically analyzed at mid-systolic frame. (A) 3D mitral 
annulus area, (B) mitral annulus area at the best fit plane, (C) Inter-trigonal distance, (D) Aorto-
Mitral angle 
 
 
Statistical analysis 
 
The normal distribution of the variables was checked using the Kolmogorov-Smirnov test. 
Continuous data are presented as mean ± standard deviation (SD) or Median (25°-75°) and categorical 
variables as absolute numbers and percentages, as appropriate. In the validation study, the relationship 
between TTE mid-systolic MA parameters measured using the two software packages, and mid-
systolic and early-diastolic parameters measured using TTE and TEE data sets in the same patient, 
were evaluated using Pearson or Spearman correlation. Bland–Altman plots were used to assess the 
mean difference and the limits of agreement between them. Paired t test or Wilcoxon rank test were 
used, as appropriate, for comparing the MV dimension obtained by TTE and TEE data set in the same 
patient.  
Variables were compared between IMR and nIMR patients using the unpaired t or the Mann-Whitney 
tests, as appropriate. Chi-square was used to compare the categorical variables. A paired t test or 
 57 
Wilcoxon signed rank test was used to compare systolic and diastolic dimensions within the same 
subgroups, as appropriate. Percentage change of the systo-diastolic measurements was calculated. 
Data analyses was performed using SPSS version 20.0 (SPSS, Inc, Chicago, IL) and GraphPad Prism 
V 7 (GraphPad Software, La Jolla, CA). Differences among variables were considered significant at 
p value < 0.05.  
 
Results 
 
Validation study 
 
The TTE validation cohort included 30 patients (15 with IMR; 22 men; mean age 64±2 year) with 
good image quality. The temporal resolution of the 3D dataset for MV quantification was 35±3 
volumes per second (vps). Close correlations and good agreements were found between the 
measurements obtained with the two software packages. (Figures 34-36)  
 
 
Figure 34 Comparisons of mitral annulus diameter measured by GE and TomTec software using 
Pearson correlation (top) and Bland–Altman (bottom) analyses 
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Figure 35 Comparisons of mitral annulus area and perimeter measured by GE and TomTec 
software using Pearson correlation (top) and Bland–Altman (bottom) analyses 
 
 
Figure 36 Comparisons of mitral annulus tenting value measured by GE and TomTec software 
using Pearson correlation (top) and Bland–Altman (bottom) analyses 
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The TEE validation cohort included 15 patients (8 with IMR; 14 men; mean age 63±15 year). As 
expected, both image quality (excellent quality in 75% versus 25%, respectively, p=0.009) and 
temporal resolution (34±15 vps versus 29±10 vps, respectively, p<0.05) were higher for TEE than 
TTE data sets. The mean time lapse between TTE and TEE data set acquisitions was 1(0-6) day. 
Measurements obtained from TEE data sets resulted in slightly larger area, perimeter and AP diameter 
(Table 5). However, there was a close correlation between the two techniques and the differences 
were not clinically relevant. Among linear dimension, ALPM, commissural diameter and diastolic 
inter-trigonal distance are the most similar in TEE and TTE data sets, while tenting area, tenting 
volume and non-planar showed the largest differences. (Table 5) (Figure 37-41) 
 
 
Figure 37 Comparisons of mitral annulus early-diastolic diameter measured by transthoracic and 
transesophageal echocardiography using the same software package using Pearson correlation 
(top) and Bland–Altman (bottom) analyses 
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Figure 38 Comparisons of mitral annulus early-diastolic area and perimeter measured by 
transthoracic and transesophageal echocardiography using the same software package using 
Pearson correlation (top) and Bland–Altman (bottom) analyses 
 
 
 
 
 
Figure 39 Comparisons of mitral annulus mid-systolic diameter measured by transthoracic and 
transesophageal echocardiography using the same software package using Pearson correlation 
(top) and Bland–Altman (bottom) analyses 
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Figure 40 Comparisons of mitral annulus mid-systolic area and perimeter measured by 
transthoracic and transesophageal echocardiography using the same software package using 
Pearson correlation (top) and Bland–Altman (bottom) analyses 
 
 
 
 
 
Figure 41 Comparisons of mitral annulus tenting value measured by transthoracic and 
transesophageal echocardiography using the same software package using Pearson correlation 
(top) and Bland–Altman (bottom) analyses 
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Table 5 Comparison of mitral annulus parameter among transthoracic and transoesophageal 
data sets  
 Transthoracic 
N=15 
Transoesophageal 
N=15 
p r 
Diastolic dimension 
Annulus area (3D) (cm2) 11.5 ± 3.1 12.4 ± 3.2 0.031 0.879** 
Annulus best fit plane (cm2) 10.6 ± 3.0 11.7 ± 3.1 0.016 0.869** 
Annulus perimeter (cm) 12.1 ±1.7 12.6 ± 1.6 0.036 0.883** 
AP diameter (cm) 3.5 ± 0.5 3.8 ± 0.5 0.012 0.799** 
ALPM diameter (cm) 3.7 ± 0.5 3.8 ± 0.5 0.342 0.840** 
Commissural diameter (cm) 3.7 ± 0.4 3.8 ± 0.5 0.231 0.777** 
Itertrigonal distance (cm) 2.8 ± 0.3 3.0 ± 0.4 0.094 0.715** 
Sphericity index  0.9 ± 0.1 1.0 ± 0.1 0.150 0.157 
Annulus height (mm) 7.3 ± 1.7 6.8 ± 1.6 0.343 0.559* 
Non planar angle 156 ± 13 152 ± 11 0.314 0.474 
Mitro-aortic angle 131 ± 8 125 ±10 0.039 0.418 
Systolic dimension 
Annulus area (3D) (cm2) 10.2 ± 2.6 11.0 ± 2.6 0.006 0.936** 
Annulus best fit plane (cm2) 9.3 ± 2.5 10.2 ± 2.5 0.001 0.959** 
Annulus perimeter (cm) 11.4 ±1.5 11.8 ± 1.4 0.010 0.943** 
AP diameter (cm) 3.2 ± 0.4 3.4 ± 0.6 0.002 0.624* r 
ALPM diameter (cm) 3.6 ± 0.5 3.6 ± 0.4 0.329 0.857** 
Commissural diameter (cm) 3.5 ± 0.4 3.6 ± 0.4 0.151 0.889** 
Itertrigonal distance (cm) 2.6 ± 0.4 3.0 ± 0.4 0.000 0.830** 
Sphericity index  0.9 ± 0.1 0.9 ± 0.1 0.062 0.321r 
Annulus height (mm) 7.0 ± 1.3 7.0 ± 1.4 0.910 0.300 
Non planar angle (°) 153 ± 10 153 ± 9 0.893 0.240 
Aorto-mitral angle (°) 139 ±10 129 ± 8 0.005 0.367 
Tenting height (mm) 10.3 ± 2.0 7.2 ± 3.6 0.020 - 0.108 
Tenting area (cm2) 2.3 ± 0.6 2.3 ± 0.7 0.934 0.542* 
Tenting volume ( mL) 4.2 ±1.3 4.1 ± 1.5 0.742 0.747** 
Data are expressed as Mean ± Standard Deviation. Abbreviations: ALPM, anterolateral-
posteromedial, AP, antero-posterior diameter.* for correlation with p < 0.05; ** for correlation with 
p < 0.001; r evaluated with Sperman’s correlation 
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Comparison of mitral annulus geometry between ischemic and non-ischemic mitral 
regurgitation 
  
We enrolled 94 patients, 41 (43,6%) with IMR and 53 (56,4%) with nIMR. Patients with IMR were 
more frequently male and had a higher incidence of hypertension, diabetes and dyslipidemia. (Table 
6) The severity of MR was comparable between the two groups. (Table 7) Although patients in both 
groups showed severe LV dilatation and dysfunction, patients with IMR had a higher LVEF (31 (26-
38)% versus 28 (22-32)%, p=0.030) and LV wall motion score index (2.1±0.3 versus 1.9± 0.6, 
p=0.021). (Table 7) 
Temporal resolution of the 3D dataset dedicated for MV quantification was higher in IMR than in 
nIMR patients (33±14 vps versus 40±16 vps, p=0.023). All data sets had enough good quality for the 
quantitative analysis. The image quality was graded excellent in 47 patients (50%), good in 32 (34%), 
and fair in 15 (16%) and it was comparable between IMR and nIMR patients (p=0.634). 
 
Table 6 Demographics and clinical characteristics 
 Ischemic Mitral 
Regurgitation 
N=41 
Non Ischemic Mitral 
Regurgitation 
N=53 
p 
Age (years) 69 (63-75) 64 (55-72) 0.081  
Men (%) 35 (85) 35 (66) 0.033 
Body surface area (m2) 1.8 (1.7-1.9) 1.9 (1.7-2.0) 0.374 
Heart rate (bpm) 71(59-85) 75 (65-86) 0.237 
Systolic blood pressure (mmHg) 110 (100-120) 100 (95-115) 0.340 
Diastolic blood pressure(mmHg) 65(60-71) 65 (60-70) 0.233 
Hypertension 32 (80%) 25 (48.1%) 0.002 
Diabetes 15 (37.5%) 8 (15.4%) 0.015 
Dyslipidemia 30 (75%) 22 (42.3%) 0.002 
Smokers 23 (57.5%) 24 (46.2%) 0.280 
Resynchronization therapy 8 (20%) 17 (32.7%) 0.175 
 
Data are expressed as Median (25°-75°) or Number (%).  
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Using conventional two-dimensional echocardiography MV geometry parameters, patients with 
nIMR showed larger AP diameter both in diastole (41±7 mm in nIMR versus 38±6 mm in IMR, 
p=0.029) and in systole (37± 6 mm in nIMR versus 34±4 mm in IMR, p=0.024). Conversely, CC 
diameter (43±8 mm in nIMR versus 39±9 mm in IMR, p=0.088), tenting height (9±3 mm in nIMR 
versus 8.5±3 mm in IMR, p=0.180) and tenting area (1.9 ±0.7 cm2 in nIMR versus 1.7±0.6 cm2 in 
IMR, p=0.189) were similar between the two groups.  
 
Table 7 Echocardiography characteristics  
 Ischemic Mitral 
Regurgitation 
N=41 
Non Ischemic Mitral 
Regurgitation 
N=53 
p 
MR Vena contracta (mm) 7 (6-8) 7 (6-8) 0.658 
MR PISA radius (mm) 7 (6-8) 8 (7-9) 0.138 
MR EROA (mm2) 2 (2-3) 2.1(2-3) 0.421 
MR R Vol (mL) 38 (28-58) 38.5 (29-47.7) 0.803 
sPAP 47 (35-56) 44 (35-49) 0.211 
TR severity 
 
Trivial 6 (11.3%) 
Mild 29 (54.7%) 
Moderate11 (20.8%) 
Severe 7 (13.2%) 
Trivial 6 (15.4%) 
Mild 20 (51.3%) 
Moderate10 (25.6%) 
Severe3 (7.7%) 
0.753 
AR severity 
 
None 25(49%) 
Trivial 13(25%) 
Mild 12(23.5%) 
Moderate 1 (2%) 
None 25 (65%) 
Trivial 6 (15%) 
Mild 9 (22.5%) 
Moderate 0 (0%) 
0.437 
LV EDV (ml/m2) 134 (114-153) 143(116-178) 0.078 
LV ESV (mL/m2) 96 (68-109) 105 (78-135) 0.075 
Ejection Fraction (%) 31 (26-38) 28 (22-32) 0.030 
Indexed LA volume (mL/m2) 60 (51-68) 70 (53-91) 0.031 
Data are expressed as Median (25°-75°) or Number (%).  
Abbreviations: AR, aortic regurgitation; EROA, effective regurgitant orifice area; LA, left atrial; LV 
EDV, left ventricular end-diastolic volume, LV ESV, left ventricular end-systolic volume; MR, mitral 
regurgitation; PISA, proximal isovelocity surface area; R Vol, regurgitant volume; sPAP, systolic 
pulmonary artery pressure; TR, tricuspid regurgitation.  
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At 3DE analysis, both subgroups had similar diastolic geometry of MA, even though all MA 
dimensions were slightly larger in nIMR. nIMR patients showed larger mid-systolic 3D area and 
perimeter of the MA with longer leaflets. However, the area of the annulus at the best fit plane, and 
all diameters (AP, CC, ALPM diameter and trans-trigonal distance) did not differ between IMR and 
nIMR patients. Tenting height and area did not differ between IMR and nIMR patients, whereas 
tenting volume, annulus height and aorto-mitral angle were larger in nIMR patients. (Table 9)  
 
 
Mitral annulus dynamics 
In both groups, MA significantly reduced its dimensions in systole (except for CC diameter) with 
similar percentage change of the measurement in both groups (p>0.05). (Table 8 and 9) During 
systole, the MA mitral-aortic angle flattens, while the non-planarity angle becomes more acute.  
 
Table 8 Fractional changes of the mitral annulus parameters between diastole and systole  
 Ischemic Mitral 
Regurgitation 
N=41 
Non Ischemic Mitral 
Regurgitation 
N=53 
p 
MA area (3D) fraction (%) -6 (-11.7 – -1.8) - 4.3 (-9.8 – -1.3) > 0.05 
MA best fit plane fraction (%)  -6.3 (-13 – -4) -6.7 (-11.4 – -1.8) > 0.05 
MA perimeter fraction (%) -3.2 (-5.8 – - 0.4) -2.1 (-4.6 – -0.8) > 0.05 
AP diameter fraction (%) -7.4 (-11.4 – -2.4) -5.9 (-11.2 – -1.3) > 0.05 
ALPM diameter fraction (%) -2.9 (-6.9 – -0.0) 0.0 ( -7.3 – 0.0) > 0.05 
CC diameter fraction (%) -2.6 (-5.5 – 2.9) 0.0 (-4.7 – 2.7) > 0.05 
TT distance fraction (%) -4.8 (-12.4 – 0.0) -3.1 (-10 – 3.8) > 0.05 
Non planar angle fraction (%) -2 (-6.3 – 2.5) -2.4 ( -5.6 – 2) > 0.05 
Aorto-mitral angle fraction (%) 3.7 ( -2.5 – 8.4) 3.4 (0 – 8.4) > 0.05 
 
Data are expressed as Median (25°-75°). 
Abbreviations: ALPM, anterolateral-posteromedial; AP, antero-posterior diameter; CC, 
commissural; MA, mitral annulus; TT, trans-trigonal. 
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Table 9 Three-dimensional mitral valve dimension 
 Ischemic Mitral 
Regurgitation 
N=41 
Non Ischemic Mitral 
Regurgitation 
N=53 
p 
Diastolic dimension 
Annulus area (3D) (cm2) 10.7 ± 2.5* 11.6 ± 2.7* 0.124 
Annulus best fit plane (cm2) 9.9 ± 2.3* 10.7 ± 2.5* 0.135 
Annulus perimeter (cm) 11.7 ±1.4* 12.2 ± 1.4* 0.111 
AP diameter (cm) 3.3 ± 0.4* 3.5 ± 0.5* 0.072 
ALPM diameter (cm) 3.6 ± 0.4* 3.8 ± 0.5* 0.129 
Commissural diameter(cm) 3.6 ± 0.4 3.7 ± 0.4 0.300 
Itertrigonal distance (cm) 2.7 ± 0.4* 2.8 ± 0.3* 0.374 
Annulus height (mm) 6.3 ± 1.7* 6.8 ± 1.7* 0.144 
Sphericity index  0.9 ± 0.1* 0.9 ± 0.1* 0.963 
Non planar angle (°) 156 ± 11* 153 ± 10* 0.232 
Anterior leaflet area (cm2) 7.5 ±1.6* 8.0 ± 1.6* 0.142 
Posterior leaflet area (cm2) 7.2 ±2.3* 7.5 ± 2.1* 0.413 
Anterior leaflet length (cm) 2.9 ±0.4 3.3 ±0.9* 0.102 
Posterior leaflet length (cm) 1.6 ± 0.4* 1.7 ± 0.6* 0.319 
Aorto-mitral angle (°) 131 ± 9* 135 ± 11* 0.115 
Systolic dimension 
Annulus area (3D) (cm2) 9.8 ± 2.3 10.8 ± 2.7 0.046 
Annulus best fit plane (cm2) 9 ± 2.1 9.9 ± 2.5 0.063 
Annulus perimeter (cm) 11.2 ±1.3 11.8 ± 1.5 0.048 
AP diameter (cm) 3.1 ± 0.4 3.2 ± 0.5 0.063 
ALPM diameter (cm) 3.5 ± 0.4 3.7 ± 0.5 0.065 
Commissural diameter(cm) 3.5 ± 0.4 3.7 ± 0.4 0.130 
Itertrigonal distance (cm) 2.5 ± 0.3 2.7 ± 0.3 0.051 
Annulus height (mm) 6.7 ± 1.6 7.5 ± 1.9 0.047 
Sphericity index  0.9 ± 0.08 0.9 ± 0.1 0.598 
Non planar angle (°) 153 ± 11 150 ± 10 0.268 
Anterior leaflet area (cm2) 6.5 ± 1.6 7.4 ± 1.7 0.006 
Posterior leaflet area (cm2) 5.7 ± 1.7 6.5 ± 1.9 0.049 
Anterior leaflet length (cm) 2.8 ± 0.6 3 ± 0.4 0.022 
Posterior leaflet length (cm) 1.3 ± 0.4 1.5 ± 0.8 0.022 
Aorto-mitral angle (°) 135 ± 10 141 ± 11 0.011 
Tenting height (mm) 9.3 ± 2.6 10.3 ± 2.8 0.082 
Tenting area (cm2) 2.2 ± 0.7 2.4 ± 0.8 0.141 
Tenting volume (mL) 4 ±1.7 4.7 ± 1.7 0.047 
Data are expressed as Mean ± Standard Deviation.  
Abbreviations: ALPM, anterolateral-posteromedial, AP, antero.posterior diameter.  
* Statistical difference vs systolic dimension 
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Discussion 
 
1) Preclinical study assessing the feasibility and early safety of a novel mitral valve self-expandable 
prosthesis  
 
The pre-clinical assessment of the safety and feasibility of the Epygon transcatheter bioprosthetic 
mitral valve implantation showed favorable results. In the sheep model, the implantation was feasible 
across different anatomic subsets and short-term safety was acceptable. The sheep model is 
considered the gold standard for testing the performance of novel prostheses at long-term follow-up 
because tissue leaflets are prone to accelerated calcification and degeneration. In addition, findings 
in the sheep model can be more easily generalized because the MA shape is comparable to the adult 
human and does not change significantly over a 5-month period compared with the swine model.6 
The Epygon valve is a catheter-based self-expanding mitral bioprosthesis specifically designed to fit 
the complex anatomic structure of the mitral apparatus. Among the singular characteristics of the 
Epygon prosthesis, the asymmetric nitinol stent and the advanced mono-leaflet structure need to be 
mentioned. These two key components are designed to replicate the normal anatomy and function of 
the MV, which has indeed D-shape and larger anterior leaflet.  
Each transcatheter mitral valve prosthesis has some unique features but also generally shares some 
characteristics with others. As the Epygon prosthesis, also the Tiara, Tendyne and Caisson systems 
have a D-shaped stent. The Tendyne and Caisson prostheses are characterized by a D-shaped outer 
frame that anchor the native mitral valve annulus and a circular inner frame with a three porcine 
pericardium leaflets. Tiara prosthesis has three leaflets made of bovine pericardium and is 
characterized by an atrial skirt and a ventricular anchoring system. The Epygon prosthesis has anterior 
and posterior paddles to catch MV leaflets as the Tiara and the Fortis systems. As many other 
competitor bioprostheses, the Epygon was primarily developed for the TA approach; however TS 
implantation is under development. 
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2) Evaluation of the prosthesis function by hemodynamic surrogate parameters and blood flow 
characteristics  
The favorable post-procedural hemodynamic results were evaluated by using Doppler quantification 
and both 2D and 3D echocardiography as described in the proper section.  
The analysis was complemented by echocardiography particle imaging velocimetry (Echo-PIV) 
which is an emerging imaging technique enabling the assessment of the intraventricular fluid dynamic 
and the characterization of diastolic vortex formation as expression of the LV filling efficiency.98,99 
In the LV, the laminar mitral inflow is converted into a vortex at the tips of the mitral valve leaflets 
which maintains the momentum of the blood flow and allows its smooth redirection towards the 
outflow tract during systole with minimal generation of turbulence and consequent avoidance of large 
loss of kinetic energy.100,101 Because of fluid viscosity, a blood flow vortex loses energy. The energy 
loss is particularly high if there are rapid changes in vorticity (high pulsatility) or if many small 
vortices interact (turbulence).102 In case of energetically unfavourable conditions, kinetic energy gets 
lost with higher demand to the LV muscle in the following cardiac cycle.102 
Faludi and colleagues assessed vortex formation in healthy subjects and the effects of different types 
of prosthetic valves on intraventricular flow patterns and flow-mediated energy dissipation.102 In 
healty subjects, vortex detaches from the anterior leaflet of the mitral valve at the beginning of early-
diastolic philling, rotates clockwise in the 3- chamber view and fills almost the entire LV by the end 
of early-diastolic philling. At the very end of diastole, a single large vortex is present, and blood is 
smoothly redirected toward the outflow tract for the following systole. In patients with mechanical 
bi-leaflet valve in anatomic orientation (hinge positions approximating commissures of the previous 
native valve), the resulting vorticity pattern is opposite to that seen in healthy hearts, characterized 
by a large counterclockwise rotating vortex. The flow through a bioprosthesis generates a central jet 
directed toward the apex, with loss of the symmetry of flow pattern and crossing with preceding 
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inflow area of the outflowing blood during systole. Moreover, in patients with bioprosthetic and 
mechanical valves, the parameters of energy dissipation were higher than in healthy subjects.102,103 
Our preliminary analysis on 14 sheep seems supporting the hypothesis that the Epygon bioprosthesis 
by means a physiological-like inflow area respects a normal flow pattern towards the LV. Similar to 
previous findings,102,103 we showed a significant increase in energy dissipation (energy loss) after 
device implantation, though the amount of loss was 30% lower than elsewhere reported.103 
Recent fluid dynamic data demonstrated that in normal LV the blood flow is characterized by a 
longitudinal alignment along the base–apex direction of the intraventricular hemodynamic pattern in 
compliance with the emptying-filling process.104 Conversely, HF patients or non-responders to the 
resynchronization therapy show an irregular vortex formation with local stagnation resulting in 
transversal forces and loss of the physiological longitudinal orientation of the intraventricular 
velocities.98,99,105 
After implantation of the Epygon bioprosthesis, the dominant direction of blood flow momentum 
presented a statistically significant variation, though the magnitude of the change was trivial. This 
finding could be partially explained by the presence of suture stiches used for trans-apical access 
closure that did not allow placing the probe exactly in the same point before and after intervention 
with unavoidable influences on the assessment of the orientation of the LV long axis. In addition 
despite the observed variation, the main axis of blood flow still remained roughly parallel to the LV 
axis as expression of an efficient pattern within the LV. 
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3) Assessment of the mitral valve anatomy using three-dimensional echocardiography in patients 
with functional mitral valve regurgitation focusing on the anatomical implications for prosthesis-
based transcatheter approach 
 
In the present study, we used 3D TTE to compare MA geometry in patients with severe ischemic and 
non-ischemic FMR, who are potential candidates for TMVR.  
The main findings of our study were in patients with FMR: i, diastolic MA geometry is similar in 
both nIMR and IMR patients; ii, systolic MV geometry significantly differs between the groups. 
 
Validation study 
Multimodality imaging represents the gold standard for planning transcatheter mitral valve procedure, 
TEE and multi-slice computed tomography (MSCT) playing the major role.106 Due to longer survival 
of patients with chronic heart diseases and progressive aging of the general population, the number 
of patients who could benefit of TMVR is likely to increase, and 3DTTE will be of paramount 
importance as a screening tool for the analysis of MV geometry. Previous clinical studies assessing 
MA geometry used 3DTEE data sets107,108 to obtain adequate spatial and temporal resolution for 
quantitative analysis of the MV. However, the progressive improvement of 3DE technology allows 
to obtain better and better quality 3DE data sets with TTE, too. Moreover, feasibility and 
cost/effectiveness considerations suggest that TTE approach would be better suited to screen potential 
candidates to TMVR. Accordingly, we decided to explore the use of 3DTTE data sets perform 
quantitative analysis of the MV in patients with FMR. In our patients, MA dimensions obtained from 
TTE datasets were similar to those obtained with the 3D TEE approach in the validation study.  
 
Comparison of mitral annulus dimension between ischemic and non-ischemic mitral 
regurgitation 
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We focused our study on patients with FMR because they represent the main potential target of new 
TMVR. Previous echocardiographic studies compared MA geometry between FMR patients (without 
distinction among ischemic and non-ischemic etiology) and normal subjects109,110, patients with 
organic MV disease111,112 or hypertrophic cardiomyopathy113. Other studies selected only IMR 
patients to compare with healthy subjects 114 or myxomatous MR.107 The few studies that analyzed 
the possible differences between IMR and nIMR11-14 included a limited number of patients and were 
focused only on MA size (annulus area and diameters), without any information about the MV 
geometry (MA area at the best fit plane, mitro-aortic angle, length of the anterior leaflet) which are 
crucial to select patients for TMVR.106 
In this study, we reported all MV anatomical and geometrical features that should be assessed before 
TMVR9,115 and demonstrated that patients with severe IMR and nIMR have similar, symmetrical, 
diastolic (maximal) MA dimension. The 3D MA area obtained from our patients were comparable 
with the maximum MA surface area reported by Veronesi et al.13 in a smaller group of patients using 
TTE 3DE datasets. Our results are in agreement to those reported by Daimon et al. 11 who showed 
that diastolic MA diameters did not differ among IMR and nIMR. However, the actual MA sizes in 
our patients were slightly larger than in their. This finding could be partially explained by the different 
time point selected for the analysis (mid-diastolic phase, compared to early-diastole in our study).  
While in our study mid-systolic 3D annulus area and perimeter are significantly larger in patients 
with nIMR, MA area at the best fit plane and MA diameter are similar. It has been suggested that the 
projected 3D MA area at the level of the best fit plane is the most reliable parameter of MA geometry 
to be used for planning TMVR compared to the saddle-shaped 3D area.115 Though, our MA area at 
the best fit plane resulted smaller than the mean projected MA area measured in a recent MSCT study 
116 on 32 patients with FMR of different etiologies and severity, it is already known that 3DE can 
underestimate measurement compared with MSCT due to its suboptimal lateral resolution in the 
coronal plane.117 
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A new D-shaped MA segmentation developed by Blanke et al.118, with the truncation of anterior 
saddle horn at the level of inter-trigonal line, has been used to select candidates to Tiara 6, Tendyne8 
and Intrepid7 valve implant. This method was also recently applied by Mak et al. 112 using 3D TEE 
with comparable results, but it is unclear at this early stage of TMVR experience whether this is the 
best parameter to size the prosthesis for TMVR interventions. 119 
Left ventricular out flow tract (LVOT) obstruction is a possible complication related to TMVR that 
can be predicted during procedure planning because it is related to the design of the prosthesis and 
patient anatomy (interventricular septal dimension, LV size, aorto-mitral angle, anterior leaflet 
length). MSCT virtual modelling of the prosthesis is able to “create” and quantify the neo-LVOT to 
predict the risk of LVOT obstruction.92 3DE allows the measurement of both the aorto-mitral angle 
(the angle between the aortic valve and the MA along the AP direction) and anterior leaflet length. 
None of the previous MSCT nor the 3DE studies reported these parameters in patients considered for 
TMVR. In our study we found that nIMR group presented significantly wider aorto-mitral angle that 
balance the potential higher risk of LVOT obstruction due to longer and larger anterior leaflets in 
these patients. 
 
Mitral annulus dynamics  
MA is dynamic structure characterized by an annular contraction between mid-diastole to early-
systole followed by a progressive expansion throughout the second half of the systole that reaches its 
maximum dimension during early diastolic filling.13,120 These changes, although less pronounced than 
in normal subjects, have been reported also in patients with IMR107,121 and nIMR13. We found that in 
patients with severe FMR, MA is significantly smaller in mid-systole compared to early diastolic 
phase. This findings underly the necessity of a multiphasic MA assessment to select patients for 
TMVR 9, but the few investigations that analyzed MA dimension in moderate or severe FMR 
(potentially candidates for TMVR), reported only the measurement in one phase of the cardiac 
cycle.13,14 
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In our study, the non-planarity angle, a parameter describing the ‘‘saddle-shaped’’ morphology of the 
MA, become more acute (the annulus increases its “saddleness”) whereas the mitral-aortic angle 
flattens, in systole. This finding, are in contrast to previous study of Veronesi et al. 122 in normal 
subjects, and probably this alteration may contribute to pathophysiology of FMR. 
 
Implications for trans-catheter mitral valve selection  
TMVR represents a promising option for patients with severe FMR, and assessment of MA dimension 
and geometry is of paramount importance to size the device and also to plan future development of 
new prostheses. We found that, patients with IMR and nIMR have similar MA geometry, supporting 
the concept that there is no need of different prosthesis sizing according to etiology of FMR. 
However, we found that nIMR patients had significantly larger and longer anterior mitral leaflet, that 
could increase the risk of LVOT obstruction. Therefore, for nIMR patients it could be more 
appropriate to select a device that has an anterior hook to fix the anterior leaflet of the native MV. On 
the other hand, nIMR patients showed a wider aorto-mitral angle that could counterbalance the higher 
risk of LVOT obstruction carried by longer anterior leaflet. Probably, this sub-group of patients would 
be eligible also for devices that have larger protrusion or flaring into LV.  
The significant change of MA during the cardiac cycle, also preserved in patients with severe FMR, 
stresses the need to evaluate accurately the smallest MA dimension in order to reduce the risk of 
excessive stress of the prosthesis frame by MA. 
 
Study limitations 
We acknowledge certain limitations of our study. First, to obtain all the measurements needed to plan 
TMVR from 3DE data sets, we used a new MV software package that was not previously validated. 
To overcome this limitation, we compared the measurements obtained with the new software package 
with those obtained from the same data sets using a validated software95 with a close correlations and 
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good agreement. However, we did not compare our measurement with MSCT, which represents the 
current gold standard for patient selection for TMVR.  
Secondly, currently available 3DE software packages allow MV dynamic analysis only during the 
systolic phase of the cardiac cycle; while mid-systole could be defined by the operator according to 
MV opening and closure or automatically by the software (as mid-way between R and T waves on 
the ECG tracing), early-diastole has to be manually identified by the operator with an increased 
possibility of errors. Current literature reports contradicting data about the moment when MA reaches 
its maximum and minimum sizes, however the importance of definition of maximum MA dimension 
is of paramount importance for accurate device’s sizing and emphasizes the need of multiphasic 
annular measurement.  
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Conclusions 
 
 The treatment of severe MR in patients with high surgical risk represents a new challenge for 
transcatheter therapeutic approaches. Novel TMVR systems can represent the answer for most of 
patients with complex MV anatomy, advanced disease, severe leaflet tethering or MA dilation. Early 
TMVR clinical reports showed promising results and suggested that advances in transcatheter 
strategies technology can generate in the incoming future valid therapeutic alternatives to the 
traditional surgical intervention. 
 Our initial preclinical experience with the novel bovine tissue mono-leaflet D-shaped nitinol 
frame transcatheter self-expandable mitral valve bioprosthesis by TA access showed that the correct 
implantation is feasible, safe, and associated with good post-procedural hemodynamic results. The 
application of advanced echocardiography guided valve orientation and positioning during the 
procedure, supported continuous refinements for the improvement of the bioprosthesis, and provided 
an useful tool for the assessment of the performance after implantation. The results of the ongoing 
preclinical study with the Epygon bioprosthesis are intended as background for future applications in 
the human. 
 The reported MA geometry in a relatively large group of patients with severe FMR, potentially 
candidates for TMVR, represents an useful information for transcatheter MV prosthesis design and 
patient selection. Patients with ischemic and non-ischemic etiologies of FMR have similar maximum 
dimensions, yet systolic differences between the two groups should be taken into account to tailor 
prosthesis selection.  
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